Journal articles on the topic 'Robert C. Reeves Company'
To see the other types of publications on this topic, follow the link: Robert C. Reeves Company.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Robert C. Reeves Company.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Liu, Hai Ying. "An Empirical Study on Board Characteristics and Sustainable Growth of Listed Company." Advanced Materials Research 403-408 (November 2011): 2526–29. http://dx.doi.org/10.4028/www.scientific.net/amr.403-408.2526.
Full textAbstract:
The paper is based on the SGR model by Robert C Higgins. Through regression analysis and panel data, we find that the diligent boards and the stock-keeping ratio of board directors are associated with higher sustainable growth, while board size can restrain sustainable growth to some extent,With respect to the other variables, results indicate that CEO-duality and percent of independent directors on the board do not significantly influent sustainable growth.
2
Clarke, John. "The Canada Company and the Huron Tract 1826-1853: Personalities, Profits and Politics. By Robert C. Lee." Ontario History 97, no. 2 (2005): 231. http://dx.doi.org/10.7202/1065888ar.
Full text
3
Withers, D. M. "Enterprising Women: Independence, Finance and Virago Press, c.1976–93." Twentieth Century British History 31, no. 4 (December 28, 2019): 479–502. http://dx.doi.org/10.1093/tcbh/hwz044.
Full textAbstract:
Abstract Virago Press were established in 1972 and became one of the twentieth century’s most enduring publishing brands. As a women-led enterprise, articulations of independence have defined key moments in Virago’s history. This article explores two moments when the company re-structured as independent, in 1976 and 1987. To become successful, Virago had to overcome barriers that have historically hindered women’s participation in business, namely limited social capital and difficulties accessing finance. Virago founder Carmen Callil’s friendship with publisher Paul Hamlyn and printing entrepreneur Robert Gavron embedded Virago in networks of male entrepreneurial knowledge that helped shape the evolution of the company. Such networks were vital to Virago securing investment from Rothschilds Ventures Limited in 1987 who were, at that time, leading figures in the UK’s growing private equity industry. This article contributes to growing historical understanding of the synergies between financial, arts and culture industries in the 1980s. It argues that while this era offered new opportunities for women to participate in business, such participation was tempered by new forms of legal and financial discipline that re-calibrated existing gender inequalities within business cultures. Due to the time periods under consideration, this article also analyses how entrepreneurial practices and opportunities for women changed dramatically with the onset of Thatcher’s ‘Enterprise Culture’.
4
Wacker, Grant. "The New Christian Right: Mobilization and Legitimation. Edited by Robert C. Liebman and Robert Wuthnow. New York: Aldine Publishing Company, 1983. viii + 256 pp. $16.95." Church History 54, no. 3 (September 1985): 436–37. http://dx.doi.org/10.2307/3165724.
Full text
5
Boyle, Carol A. J. "THE EVALUATION AND TREATMENT OF MYOPATHIES. 1995. By Robert C. Griggs, Jerry R. Mendell, Robert G. Miller. Published by F.A. Davis Company. 510 pages. $C180.00 approx." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 23, no. 1 (February 1996): 87–88. http://dx.doi.org/10.1017/s0317167100039330.
Full text
6
Head, Anita K. "Legal Drafting. By Robert C. Dick. 2nd ed. Toronto, Ontario, Canada: Carswell Company, Ltd., 1985. Pp. xiii, 234, (hardbound)." International Journal of Legal Information 14, no. 1-2 (April 1986): 80–81. http://dx.doi.org/10.1017/s0731126500019715.
Full text
7
Bahn, Peter R. "Symphony in C: Carbon and the Evolution of (Almost) Everything by Robert M. Hazen, W.W. Norton & Company, 2019." Origins of Life and Evolution of Biospheres 50, no. 1-2 (February 13, 2020): 97–98. http://dx.doi.org/10.1007/s11084-020-09592-y.
Full text
8
Kaye, J. H. "Book Reviews : Managing Human Relations -- Concept and Practices by Robert E. Callahan and C. Patrick Fleenor. (1988). Merrill Publishing Company." Asia Pacific Journal of Human Resources 28, no. 1 (February 1, 1990): 91–92. http://dx.doi.org/10.1177/103841119002800109.
Full text
9
Pryse-Phillips, William. "DIZZINESS, HEARING LOSS AND TINNITUS. 1998. By Robert W. Baloh. Published by F.A. Davis Company. 256 pages. C$84.50 approx." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 27, no. 1 (February 2000): 89. http://dx.doi.org/10.1017/s0317167100052136.
Full text
10
Parrish, Michael. "The Soviet Military Encyclopedia, Abridged English Language Edition, vols. 1-4. Eds. and trans. William C. Green and W. Robert Reeves. Boulder: Westview Press, 1993. 640 pp. $95.00 each, hard bound." Slavic Review 53, no. 2 (1994): 649–50. http://dx.doi.org/10.2307/2501389.
Full text
11
Billington, Louis. "Robert C. Liebman and Robert Wuthnow (eds.), The New Christian Right: Mobilization and Legitimation (New York: Aldine Publishing Company, 1983, $16.95). Pp. viii, 256. ISBN 0 202 30307 1." Journal of American Studies 19, no. 2 (August 1985): 280–81. http://dx.doi.org/10.1017/s0021875800012226.
Full text
12
Danon, J. M. "Evaluation and treatment of myopathies Editors: Robert C. Griggs, Jerry R. Mendell, and Robert G. Miller, F.A. Davis Company, 1915 Arch St., Philadelphia, PA 19103, 1995, 5160 pp., $135.00." Muscle & Nerve 18, no. 12 (December 1995): 1498. http://dx.doi.org/10.1002/mus.880181226.
Full text
13
Griffin, Stephen. "European Company Laws ed by Robert R. Drury & Peter C. Xuereb Aldershot: Dartmouth Publishing, 1990, x + 278 + (index) 5 pp (hardback £37.50)." Legal Studies 12, no. 1 (March 1992): 131–33. http://dx.doi.org/10.1017/s0261387500012691.
Full text
14
Berry, G. "Essentials of biostatistics, Robert C. Elston and William D. Johnson, F. A. Davis company, Philadelphia, 1987. no. of pages XII + 307. price: £19.65." Statistics in Medicine 7, no. 11 (November 1988): 1204. http://dx.doi.org/10.1002/sim.4780071115.
Full text
15
Birch, Jonathan C. P. "Review essay: When the dancing turned to mourning: Theological responses to the pandemic." Theology in Scotland 28, no. 1 (March 10, 2021): 62–80. http://dx.doi.org/10.15664/tis.v28i1.2186.
Full textAbstract:
This review essay considers four books published within the first months of the COVID-19 pandemic. It guides us through how each of these texts offers a timely Christian response to, and not explanation for, the challenges that we face: innumerable deaths, the inability to worship together, deserted streets and shut-up businesses, the place of viruses in the Earth’s ecology, and the apparent absence of God as the innovations of modern science seem to be our only salvation. Reviewed works:John C. Lennox, Where is God in a Coronavirus World? (Epsom, Surrey: The Good Book Company, 2020)Tom Wright, God and the Pandemic: A Christian Reflection on the Coronavirus and its Aftermath (London: SPCK: 2020)Walter Brueggemann, Virus as a Summons to Faith: Biblical Reflections in a Time of Loss, Grief, and Uncertainty (Milton Keynes: Paternoster, 2020)Robert Keay, Reframing Pandemic (The Window of Christianity series; New York: Basiliad Publishing, 2020)
16
Toorabally, Milad, Damien Bregiroux, Natacha Krins, Arvinder Singh, Damien Dambournet, and Christel Laberty-Robert. "A Negative-Based TiO2 Electrode for Aqueous Proton Batteries." ECS Meeting Abstracts MA2023-01, no. 1 (August 28, 2023): 459. http://dx.doi.org/10.1149/ma2023-011459mtgabs.
Full textAbstract:
Complementary solutions to Li-ion batteries must be studied for the growing need for energy demand. Accordingly, we have been interested in developing negative electrode materials of TiO2 capable of reversibly intercalating proton ions for aqueous batteries. One of these batteries’ main challenges comes from the low potential window available. Aqueous batteries cannot provide sufficient energy density with a thermodynamic working potential of only 1.23V. To do so, we have optimized the intrinsic transport properties of proton-ions can lead to the reduction of side reactions such as Hydrogen Evolution Reaction (HER). Solvothermal route synthesis made at different temperatures (from 90°C to 150°C) gives access to different TiO2 structures. At 90°C, a lamellar type lepidocrocite is obtained, including sheets of “TiO2” and water in the inter-lamellar spaces. This inter-lamellar space allows proton conduction by the Grotthus mechanism [1]. But, lepidocrocite type TiO2has been shown to be a non-conductive ionic conductor. To make it conductive, different cations can be inserted into the inter-lamellar space during the solvothermal synthesis, thus allowing the reorganization of water molecules, then facilitating the intercalation, conduction, and diffusion of protons [2]. Several levels of Zn2+ were tested: from 10 to 50 mol% relative to Ti4 +. At 150°C, we have been able to stabilize a complete condensed anatase (one polymorph of TiO2) phase while a defect anatase phase has been synthesized at a temperature between 90°C and 150°C. Interestingly, the quantity of defect can be tuned by the temperature and the hydrolysis ratio, h=nH2O/nTi=3.33 [3]. These defects are mainly cationic vacancies, thanks to X-Ray Pair Distribution Function (PDF) analysis. The electrochemical properties of these materials (shaped with carbon black as conductive support and Nafion as a binder) were studied in half-cell aqueous electrolyte buffered at pH 5 (CH3COOH/CH3COOK, pKa = 4.76, (1M)). Experimental capacities of more than 100 mAh/g, 80% of coulombic efficiency over 100 cycles have been obtained and potentials down to -1.4V (V vs Ag/AgCl, KCl saturated) have been achieved. For defective anatase (synthesized at 110°C), the CV curves exhibit two distinct peaks that can be linked to the co-existence of two sites for proton intercalation. The proton can be intercalated either inside a vacancy or within the lattice. This behavior allows a promising working potential of -1.6V with a gravimetric capacity of 250 mAh.g-1 with a 90% of efficiency over 50 cycles. Finally, the relationship between structure and electrochemical properties will be discussed in this presentation with the objective of designing an efficient MnO2/TiO2 aqueous battery. REFERENCE: [1] Wu, X.; Hong, J. J.; Shin, W.; Ma, L.; Liu, T.; Bi, X.; Yuan, Y.; Qi, Y.; Surta, T. W.; Huang, W.; Neuefeind, J.; Wu, T.; Greaney, P. A.; Lu, J.; Ji, X. Nat. Energy 2019, 4 (2), 123–130 [2] Chimie, E. D.; Analytique, C.; Centre, D. P.; Kang, P. S. Sorbonne Université Design de Matériaux Lamellaires Par Chimie Douce Pour Batteries à Proton et Ion Multivalent. 2020. [3] Kang, S; Singh. A; Badot, J-c; Reeves, K; Durand-Vidal, Serge, Legein, C; Body, Monique, Dubrunfaut, O; Borkiewez, O; Tremblay, B; Laberty-Robert, C; Dambournet, D Chemistry of Materials 2020 32 (21), 9458-9469 Figure 1
17
Welsh, Jennifer L. "Robert Lutton and Elisabeth Salter ,eds Pieties in Transition: Religious Practices and Experiences, c. 1400–1640. Aldershot : Ashgate Publishing Company , 2007 ISBN: 978-0-97546-5616-6." Renaissance Quarterly 61, no. 1 (2008): 278–80. http://dx.doi.org/10.1353/ren.2008.0007.
Full text
18
Clarke, Alan. "Book Reviews : ROBERT C. BERRY, WILLIAM B. GOULD IV and PAUL D. STAUDOHAR (1986) Labor Relations In Professional Sports. Auburn House Publishing Company, Dover, Massachusetts, USA. 289 pages." International Review for the Sociology of Sport 23, no. 1 (March 1988): 67–70. http://dx.doi.org/10.1177/101269028802300107.
Full text
19
Gertsch, Marc. "Basic dysrhythmias: Interpretation and management By Robert J. Huszar the C. V. Mosby Company, St. Louis, Washington, Toronto (1988) 287 pages, illustrated, $19.95 ISBN: 0-8016-2410-X." Clinical Cardiology 12, no. 6 (June 1989): 360. http://dx.doi.org/10.1002/clc.4960120614.
Full text
20
Evans, Patricia. "Book Review: Metabolic Brain Dysfunction in Systemic Disorders, edited by Allen I. Arieff and Robert C. Griggs. Published in 1992 by Little, Brown & Company, Boston, 477 pages, $115.00." Journal of Child Neurology 8, no. 3 (July 1993): 283. http://dx.doi.org/10.1177/088307389300800323.
Full text
21
Benton, Gregor. "Laszlo Ladany. The Communist Party of China and Marxism 1921–1985. A Self-Portrait. With a Foreword by Robert Elegant. C. Hurst & Company, London1988. xx, 588 pp. £ 32.50." International Review of Social History 33, no. 3 (December 1988): 354–57. http://dx.doi.org/10.1017/s0020859000008920.
Full text
22
Oliver, Eileen Iscoff. "Book Reviews : Teaching Strategies: A Guide to Better Instruction, Second Edition Donald C. Orlich, Robert J. Harder, Richard C. Callahan, Constance H. Kravas, Donald P. Kauchak, R. A. Pendergrass, and Andrew J. Keogh D. C. Heath and Company Lexington, Massachusetts, 1985 379 pp." Journal of Teacher Education 36, no. 6 (November 1985): 62–63. http://dx.doi.org/10.1177/002248718503600611.
Full text
23
Mease, P. J., T. Mallick-Searle, E. Johnston, L. Viktrup, D. Menuet, R. Yang, and R. J. Fountaine. "POS1088 EFFICACY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE OR HIP: A POST-HOC SUBGROUP ANALYSIS OF PATIENTS FROM A RANDOMIZED, NSAID-CONTROLLED STUDY WITH A HISTORY OF DEPRESSION, ANXIETY, OR INSOMNIA." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 823–24. http://dx.doi.org/10.1136/annrheumdis-2021-eular.166.
Full textAbstract:
Background:Tanezumab is a monoclonal antibody directed against nerve growth factor. It is in development for the treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom other treatments are ineffective or not appropriate. Phase 3 clinical trials have demonstrated the efficacy of subcutaneous tanezumab versus placebo for pain and function outcomes over various timepoints. Largely similar change from baseline was demonstrated in an oral nonsteroidal anti-inflammatory drug (NSAID)-controlled study.1,2,3,4 The efficacy of some other OA therapies can be dampened in patients with depression, anxiety, or insomnia.5,6,7Objectives:A post-hoc analysis to explore the efficacy of subcutaneous tanezumab after 16 weeks treatment, as compared to oral NSAID, in patients with OA and a history of depression, anxiety, or insomnia at baseline.Methods:Subgroup analysis of data from a randomized, double-blind, double-dummy, active-controlled phase 3 study of subcutaneous tanezumab (2.5 mg or 5 mg every 8 weeks) vs twice daily oral NSAID in patients (≥18 years) with radiographically-confirmed moderate to severe hip or knee OA (Kellgren-Lawrence grade ≥2; NCT02528188).4 Co-primary efficacy endpoints were change from baseline to week 16 in Western Ontario and McMaster Universities OA Index (WOMAC*) Pain and Physical Function subscale scores (both ≥5/10 at randomisation; increasing score indicates increasing pain/disability), and Patient’s Global Assessment of OA (PGA-OA, ≥3/5 at randomisation; increasing score indicates poorer condition). Enrolled patients had a history of inadequate pain relief with acetaminophen; inadequate pain relief with/intolerance to/contraindication to tramadol or opioids; or an unwillingness to take opioids. Patients were on a stable dose of NSAID for ≥30 days before screening. Data are presented as least squares (LS) mean change from baseline to week 16 for the whole population and for subgroups of patients with/without a history of depression, anxiety, or insomnia at baseline. Exploratory statistical analysis was conducted by analysis of covariance. P values were not adjusted for multiplicity. This exploratory post-hoc analysis was not part of the pre-specified hypothesis testing plan or included in any sample size calculations; therefore, comparisons between treatment arms or patient subgroups should be interpreted with caution.Results:Overall, 2996 patients were randomized and received at least one dose of study treatment (subcutaneous tanezumab 2.5 mg: n=1002; subcutaneous tanezumab 5 mg: n=998; oral NSAID: n=996). In this population (comprising patients with or without a history of anxiety, depression or insomnia), all treatments were associated with notable and largely similar magnitude improvements in WOMAC Pain, WOMAC Physical Function, and PGA-OA at week 16 (Figure 1). Across treatment groups, differences in LS mean change from baseline in patients with and without a history of depression, anxiety or insomnia ranged between 0 - 0.34 for WOMAC Pain and Physical Function and 0 - 0.19 for PGA-OA.Conclusion:Patients with a history of depression, anxiety, or insomnia did not appear to experience dampened improvements in pain or function with tanezumab or NSAID, as compared to those without.References:[1]Schnitzer T, et al. JAMA. 2019;322(1):37-48;[2]Berenbaum F, et al. Ann Rheum Dis. 2020;79(6):800-10;[3]Schnitzer T, et al. Semin Arthritis Rheum. 2020;50(3):387-93;[4]Hochberg M, et al. Arthritis Rheumatol. In Press;[5]Sharma A, et al. Open Access Rheumatol. 2016;31(8):103-13;[6]Mallen C, et al. PLoS Med. 2017;14(4):e1002273;[7]Campbell C, et al. Arthritis Care Res. 2015;67(10):1387-96.Acknowledgements:Study sponsored by Pfizer and Eli Lilly and Company. Editorial support was provided by Jennifer Bodkin of Engage Scientific Solutions and funded by Pfizer and Eli Lilly and Company.Disclosure of Interests:Philip J Mease Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Eli Lilly and Company, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly and Company, Novartis, Pfizer, Sun, UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Eli Lilly and Company, Novartis, Pfizer, Sun, UCB, Theresa Mallick-Searle Speakers bureau: Allergan, Abbvie, Eli Lilly and Company, Salix, Consultant of: Pfizer, Eli Lilly and Company, Elizabeth Johnston Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Lars Viktrup Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Dominique Menuet Employee of: Pfizer, Ruoyong Yang Employee of: Pfizer, Robert J Fountaine Shareholder of: Pfizer, Employee of: Pfizer.
24
Burke, John M., Gustavo Fonseca, Wojciech Jurczak, Jason Melear, Miguel Islas-Ohlmayer, James A. Reeves, Parameswaran Venugopal, et al. "Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)." Blood 138, Supplement 1 (November 5, 2021): 527. http://dx.doi.org/10.1182/blood-2021-151054.
Full textAbstract:
Abstract Background: Patients with relapsed or refractory (R/R) DLBCL generally have a poor prognosis, particularly if they are not candidates for autologous stem cell transplantation (ASCT) or experience relapse following approved CAR-T therapies. The UNITY-NHL study systematically explored the efficacy and tolerability of the PI3K-d/CK1-e inhibitor, umbralisib, alone (umbra), and in combination with the glycoengineered anti-CD20 monoclonal antibody ublituximab (U2), followed by a cohort treated with U2 plus bendamustine (U2+benda). Herein we report on the experience in a large cohort of patients with R/R DLBCL. Methods: This study explored a sequential combination design as described above. Eligible patients had histologically confirmed R/R DLBCL and were ineligible for ASCT, with no limit on number or type of prior treatment. Umbra was given orally at 800 mg once daily in 28-day cycles (C) until disease progression or unacceptable tolerability. Ublituximab was administered intravenously (IV) on Days 1, 8, and 15 of C1, on Day 1 of C2-6, and on Day 1 every 3C through C24. Benda was administered IV (90 mg/m 2) on Days 1/2 of C1-6. Cell of origin, NGS, and c-myc (FISH) were analyzed centrally. The primary endpoint of the study was overall response rate (ORR) as assessed by an independent review committee. Secondary endpoints included duration of response, progression-free survival, time to response, and safety. Results: 226 patients with DLBCL were enrolled as follows: umbra monotherapy (n=30), U2 (n=66), and U2+benda (n=130). The population demographics included the following features: median age was 72 years (range 32-95); 59% were male; 64% of patients had stage III or IV disease; 58% were refractory to their immediate prior therapy; and the median number of prior therapies was 2 (range 1-8). There were no substantive differences in these characteristics across cohorts. Median follow-up for the umbra, U2, and U2+benda arms was 51 months (range 47-61), 46 months (range 41-57), and 40 months (range 35-47), respectively. Overall and complete response rates for the umbra mono, U2, and U2+benda arms were 13.3% (CR 3.3%), 31.8% (CR 10.6%), and 43.1% (CR 16.9%), respectively. Results pertaining to secondary endpoints are listed in Table 1. Correlation of response to cell of origin and mutation/c-myc status is ongoing and will be available at the time of presentation. Adverse events (AEs) were similar across the cohorts, with the exception of hematologic AEs which were increased in patients receiving benda. The most common all-grade AEs by treatment arm (umbra, U2, and U2+benda, respectively) were diarrhea (47%; 41%; and 48%), nausea (40%; 45%; and 45%), fatigue (33%; 30%; and 41%) and neutropenia (3.3%; 18%; and 32%). All-grade AEs of special interest included non-infectious colitis (3.3%, 1.5%, and 2.3%) and pneumonitis (3%, 1.5%, and 1.5%) in umbra, U2 and U2+benda treated patients respectively. Grade 3/4 AEs were uncommon, with the only events >10% being limited to neutropenia (11% for U2; 27% for U2+benda), and anemia (17% for U2+benda). Conclusions: In the DLBCL cohort of UNITY-NHL, the U2+benda triplet regimen was active and well tolerated in patients with R/R DLBCL who were unsuitable for transplant or who had relapsed following ASCT. Umbra monotherapy and U2 were also well tolerated but resulted in lower ORR than in the U2+benda cohort. Figure 1 Figure 1. Disclosures Burke: X4 Pharmaceuticals: Consultancy; Bristol Myers Squibb: Consultancy; SeaGen: Consultancy, Speakers Bureau; Beigene: Consultancy, Speakers Bureau; Roche/Genentech: Consultancy; Epizyme: Consultancy; Adaptive Biotechnologies: Consultancy; Kura: Consultancy; MorphoSys: Consultancy; AstraZeneca: Consultancy; Kymera: Consultancy; AbbVie: Consultancy; Verastem: Consultancy. Fonseca: Amgen: Honoraria, Speakers Bureau; Celgene/BMS: Honoraria, Speakers Bureau; Dava Oncology: Honoraria; Epizyme: Honoraria; Karyopharm: Honoraria; Sanofi: Honoraria; Abbvie: Honoraria. Jurczak: Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novo Nordisk: Research Funding; Morphosys: Research Funding; Mei Pharma: Research Funding; Merck: Research Funding; Loxo Oncology: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Research Funding; Epizyme: Research Funding; Debbiopharm: Research Funding; Celgene: Research Funding; Celtrion: Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bayer: Research Funding; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Research Funding; Sandoz: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Research Funding; TG Therapeutics: Research Funding. Melear: TG Therapeutics: Speakers Bureau; Astrazeneca: Speakers Bureau; Janssen: Speakers Bureau. Islas-Ohlmayer: Seagen Inc.: Research Funding. Reeves: Apollomics, Inc.: Research Funding; Tarveda Therapeutics: Research Funding; Ascentage Pharmaceuticals: Research Funding; Clovis Oncology: Research Funding; Arvinas: Research Funding; Pfizer: Research Funding; Ellipses: Research Funding; ImmunoGen: Research Funding; Karyopharm Therapeutics: Honoraria, Research Funding; Moderna: Research Funding; Thrive: Research Funding; Genentech: Research Funding; Incyte Corporation: Research Funding; Astellas Pharma: Research Funding; IDEAYA Biosciences: Research Funding; Pharmacyclics: Research Funding; Loxo Oncology: Research Funding; AbbVie Inc.: Research Funding; Celgene: Research Funding; GSK: Research Funding; Jiangsu Hengrui Medicine Co.: Research Funding; Arcus Biosciences: Research Funding; Calithera: Research Funding; Amgen: Research Funding; Mirati Therapeutics, Inc.: Research Funding; Array BioPharma Inc.: Research Funding; Taiho Pharmaceutical: Research Funding; Boehringer Ingelheim: Research Funding; GI Therapeutics Inc.: Research Funding; Hutchison: Research Funding; MacroGenics: Research Funding; Ipsen: Research Funding; MedImmune, LLC.: Research Funding; BeiGene: Research Funding; TG Therapeutics: Research Funding; Acerta Pharma: Research Funding; Verastem: Research Funding; Janssen Pharmaceuticals: Research Funding, Speakers Bureau; Eisai Co.: Research Funding, Speakers Bureau; Roche Pharma: Research Funding; Novartis Pharmaceuticals: Research Funding; Daiichi Sankyo: Research Funding; Arvinas: Research Funding; CytomX: Research Funding; Sermonix Pharmaceutical: Research Funding; Seattle Genetics: Research Funding; AstraZeneca: Research Funding; Evelo Biosciences: Research Funding. Wróbel: Takeda: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; BMS: Honoraria; Roche: Honoraria, Research Funding, Speakers Bureau; BeiGene: Honoraria; Janssen: Honoraria, Speakers Bureau. Pagel: Incyte/MorphoSys: Consultancy; MEI Pharma: Consultancy; Pharmacyclics/AbbVie: Consultancy; AstraZeneca: Consultancy; Gilead: Consultancy; Actinium Pharmaceuticals: Consultancy; Kite, a Gilead Company: Consultancy; Epizyme: Consultancy; BeiGene: Consultancy. Goldschmidt: Ontada: Current Employment; Blue Ridge Cancer Care: Current Employment; Amgen: Honoraria, Speakers Bureau; BMS: Honoraria, Speakers Bureau; TG Therapeutics: Honoraria; G1 Therapeutics: Honoraria, Speakers Bureau. Miskin: TG Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company. Sportelli: TG Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company. O'Connor: TG Therapeutics, Inc.: Current Employment, Current equity holder in publicly-traded company; Nomocan: Consultancy; Dren: Consultancy, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company; Myeloid Therapeutics: Consultancy, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company; Kymera: Consultancy, Current equity holder in publicly-traded company; Mundipharma: Consultancy. Ghosh: Seattle Genetics: Consultancy, Honoraria, Speakers Bureau; Genmab: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria; TG Therapeutics: Consultancy, Honoraria, Research Funding; ADC Therapeutics: Consultancy, Honoraria; Genentech: Research Funding; Karyopharma: Consultancy, Honoraria; Pharmacyclics LLC, an AbbVie Company: Consultancy, Honoraria, Research Funding, Speakers Bureau; Adaptive Biotech: Consultancy, Honoraria; Epizyme: Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Research Funding, Speakers Bureau; AbbVie: Honoraria, Speakers Bureau.
25
Smolen, J. S., L. Xie, B. Jia, P. C. Taylor, G. R. Burmester, Y. Tanaka, A. Elias, et al. "SAT0152 EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1016.1–1016. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2398.
Full textAbstract:
Background:Baricitinib (Bari) is an oral, selective and reversible Janus kinase 1 and 2 inhibitor approved for the treatment of adults with active RA. In addition to long-term safety which has been disclosed previously with data up to 7 years [1], an important clinical consideration is whether treatment efficacy can be maintained over the long term.Objectives:To evaluate the long-term efficacy of once-daily Bari 4 mg in patients with active rheumatoid arthritis (RA) who were either naïve to or who had inadequate response (IR) to methotrexate (MTX)Methods:Post hoc analyses of data from two phase 3 studies, RA-BEGIN (MTX-naïve) and RA-BEAM (MTX-IR) for 52 weeks, and one long-term extension (LTE) study (RA-BEYOND) for an additional 96 weeks were conducted (148 weeks in total). At week 52, MTX-naïve patients initially treated with MTX monotherapy, Bari 4 mg monotherapy, or Bari 4 mg +MTX in RA-BEGIN were switched to open-label Bari 4 mg monotherapy for treatment in the LTE. Similarly, at week 52, MTX-IR patients initially treated with Bari 4 mg [+ background MTX noted as (+MTX) for RA-BEAM] or adalimumab (ADA) (+MTX) in RA-BEAM were switched to open-label Bari 4 mg (+MTX) for treatment in the LTE. Patients who received placebo (+MTX) were switched to open-label Bari 4 mg (+MTX) at week 24. The analyses of efficacy (SDAI) and physical function (HAQ-DI) were conducted on all patients who were randomized into the RA-BEGIN and RA-BEAM studies and had received ≥1 dose of study drug after randomization (mITT population). The proportion of patients who reached low disease activity (LDA), as measured by SDAI ≤11, was evaluated along with change from baseline in HAQ-DI. The non-responder imputation (NRI) method was used for the categorical analysis.Results:By week 24 in RA-BEGIN (N=584), 62% of patients treated with Bari 4 mg monotherapy or Bari 4 mg +MTX achieved SDAI LDA in comparison to 40% of pts in the MTX monotherapy group; response rates seen at week 24 in the Bari treatment groups were maintained through week 148 (Fig 1A). Similarly, by week 24 in RA-BEAM (N=1,305), 52% of patients treated with Bari 4 mg (+MTX) and 50% of patients treated with ADA (+MTX) achieved a SDAI LDA in comparison to 26% of patients from the PBO (+MTX) group. The response rate seen at week 24 with Bari 4 mg and ADA were maintained through week 148, even after patients switched from ADA to Bari 4 mg at week 52 (Fig 1B). Similar improvement and maintenance patterns in physical function measured by HAQ-DI were demonstrated. The overall discontinuation rate across treatment groups from RA-BEGIN (19.5%) and RA-BEAM (14.2%) have been published. In the LTE, the discontinuation rate from Bari treatment was 13.7% for patients originating from RA-BEGIN (1.1% due to lack of efficacy, 6.4% due to safety) and 12.6% for patients originating from RA-BEAM (1.8% due to lack of efficacy, 5.9% due to safety).Figure 1.Proportion of patients achieving SDAI ≤11 in the NRI analysis†In RA-BEGIN, rescue to Bari 4 mg + MTX was offered at week 24.‡In RA-BEAM, rescue to Bari 4 mg (+ MTX) was offered at week 16. At week 24, all PBO + MTX patients were switched to Bari 4 mg + MTX.§Upon entering RA-BEYOND at week 52, MTX and ADA patients were switched to Bari 4 mg.Conclusion:Long-term treatment with Bari 4 mg demonstrated the maintenance of clinically-relevant outcomes for up to 3 years. Low discontinuation rates during the LTE indicated that Bari 4 mg treatment was well-tolerated.References:[1]Genovese et al.Annals of the Rheumatic Diseases. 2019;78:308-309.Disclosure of Interests: :Josef S. Smolen Grant/research support from: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Consultant of: AbbVie, AstraZeneca, Celgene, Celltrion, Chugai, Eli Lilly, Gilead, ILTOO, Janssen, Novartis-Sandoz, Pfizer Inc, Samsung, Sanofi, Li Xie Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Bochao Jia Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Peter C. Taylor Grant/research support from: Celgene, Eli Lilly and Company, Galapagos, and Gilead, Consultant of: AbbVie, Biogen, Eli Lilly and Company, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Roche, and UCB, Gerd Rüdiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Yoshiya Tanaka Grant/research support from: Asahi-kasei, Astellas, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers, UCB, Daiichi-Sankyo, Eisai, Pfizer, and Ono, Consultant of: Abbvie, Astellas, Bristol-Myers Squibb, Eli Lilly, Pfizer, Speakers bureau: Daiichi-Sankyo, Astellas, Chugai, Eli Lilly, Pfizer, AbbVie, YL Biologics, Bristol-Myers, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Sanofi, UCB, and Teijin, Ayesha Elias Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Anabela Cardoso Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Robert Ortmann Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Chad Walls Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Maxime Dougados Grant/research support from: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Speakers bureau: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma
26
Frosch, William A. "Effective Therapy With Borderline Patients: Case Studies—by Robert J. Waldinger, M. D., and John G. Gunderson, M. D.; Washington, D. C., American Psychiatric Press, 1989, 232 pages, $27.50; originally published by Macmillan Publishing Company, 1987." Psychiatric Services 42, no. 5 (May 1991): 543. http://dx.doi.org/10.1176/ps.42.5.543.
Full text
27
Caspers, H. "Bayard H. McConnaughey and Robert Zottoli:Introduction to Marine Biology. Fourth Edition.–With 464 figs, 637 pp. St. Louis/Toronto/London: The C. V. Mosby Company (Oxford: Blackwell Scientific Publications) 1983. ISBN 0-8016-3259-5. £ 21.95." Internationale Revue der gesamten Hydrobiologie und Hydrographie 70, no. 2 (1985): 202. http://dx.doi.org/10.1002/iroh.19850700204.
Full text
28
KITLV, Redactie. "Book Reviews." New West Indian Guide / Nieuwe West-Indische Gids 64, no. 1-2 (January 1, 1990): 51–90. http://dx.doi.org/10.1163/13822373-90002026.
Full textAbstract:
-Hy Van Luong, John R. Rickford, Dimensions of a Creole continuum: history, texts, and linguistic analysis of Guyanese Creole. Palo Alto: Stanford University Press, 1987. xix + 340 pp.-John Stewart, Charles V. Carnegie, Afro-Caribbean villages in historical perspective. Jamaica: African-Caribbean Institute of Jamaica, 1987. x + 133 pp.-David T. Edwards, Jean Besson ,Land and development in the Caribbean. London: Macmillan Caribbean, 1987. xi + 228 pp., Janet Momsen (eds)-David T. Edwards, John Brierley ,Small farming and peasant resources in the Caribbean. Winnipeg, Canada: University of Manitoba, 1988. xvii + 133., Hymie Rubenstein (eds)-Diane J. Austin-Broos, Anthony J. Payne, Politics in Jamaica. London and New York: C. Hurst and Company, St. Martin's Press, 1988. xii + 196 pp.-Carol Yawney, Anita M. Waters, Race, class, and political symbols: rastafari and reggae in Jamaican politics. New Brunswick, New Jersey: Transaction Books, 1985. ix + 343 pp.-Judith Stein, Rupert Lewis ,Garvey: Africa, Europe, the Americas. Jamaica: Institute of Social and Economic Research, 1986. xi + 208 pp., Maureen Warner-Lewis (eds)-Robert L. Harris, Jr., Sterling Stuckey, Slave culture: nationalist theory and the foundations of Black America. New York: Oxford University Press, 1987. vii + 425 pp.-Thomas J. Spinner, Jr, Chaitram Singh, Guyana: politics in a plantation society. New York: Praeger Publishers, 1988. xiv + 156 pp.-T. Fiehrer, Paul Buhle, C.L.R. James: The artist as revolutionary. New York & London: Verso, 1988. 197 pp.-Paul Buhle, Khafra Kambon, For bread, justice and freedom: a political biography of George Weekes. London: New Beacon Books, 1988. xi + 353 pp.-Robin Derby, Richard Turits, Bernardo Vega, Trujillo y Haiti. Vol. 1 (1930-1937). Santo Domingo, Dominican Republic: Fundación Cultural Dominicana, 1988. 464 pp.-James W. Wessman, Jan Knippers Black, The Dominican Republic: politics and development in an unsovereign state. Boston, London and Sidney: Allen & Unwin, 1986. xi + 164 pp.-Gary Brana-Shute, Alma H. Young ,Militarization in the non-Hispanic Caribbean. Boulder, Colorado: Lynne Rienner Publishers, Inc., 1986. ix + 178 pp., Dion E. Phillips (eds)-Genevieve J. Escure, Mark Sebba, The syntax of serial verbs: an investigation into serialisation in Sranan and other languages. Amsterdam and Philadelphia: John Benjamins Publishing Company, Creole Language Library = vol. 2, 1987. xii + 228 pp.-Dennis Conway, Elizabeth McClean Petras, Jamican labor migration: white capital and black labor, 1850-1930. Boulder and London: Westview Press, 1988. x + 297 pp.
29
Quinn, Sean, Lacramioara Ivanciu, Robert J. Davidson, Francis Ayombil, Jeffrey Crosby, Alexey Revenko, Robert A. MacLeod, Brett P. Monia, and Rodney M. Camire. "Protection of Human Factor V from Activated Protein C Using a Monoclonal Antibody-Biochemical Characterization and Evaluation Using a Mouse Injury Model." Blood 138, Supplement 1 (November 5, 2021): 2092. http://dx.doi.org/10.1182/blood-2021-153527.
Full textAbstract:
Abstract Hemophilia is an X-linked bleeding disorder resulting in deficiency of FVIII (hemophilia A; HA) or FIX (HB). Despite treatment with infused FVIII or FIX, people with hemophilia still experience joint bleeding and impaired quality of life. Furthermore, the development of neutralizing antibodies to FVIII or FIX remains a major complication of therapy. To this end, several innovative therapeutic advances which rebalance the coagulation system by targeting anticoagulant pathways (antithrombin, tissue factor pathway inhibitor, and activated protein C (APC)) are particularly interesting as they should be effective for both HA and HB, with and without inhibitors, and may also be useful to treat certain rare bleeding disorders. Many of these approaches are in clinical trials and show promise. However, each of these anticoagulant pathways target multiple coagulation factors, and APC plays an important cellular signaling role. In the current study, we developed a monoclonal antibody (GB5) that targets human FV/FVa which could serve as an alternative therapeutic approach to enhance thrombin generation and prevent bleeding in different clinical situations. Monoclonal antibody GB5 was identified following screening of hybridoma clones derived from mice immunized with human FV. The initial screen identified GB5 as an antibody that could promote thrombin generation (TG) in the presence of APC. To characterize the antibody, purified GB5 was attached to a biosensor tip and evaluated using biolayer interferometry. Analysis of biosensor tracings revealed GB5 bound specifically and with high affinity to both FV (K d = 0.6 nM; 2 experiments) and FVa (K d = 0.7 nM; 2 experiments). A TG assay with pooled normal human plasma (NHP) or HA plasma in the absence or presence of APC was used to assess the functional effects of GB5. In the absence of APC, GB5 had a minimal effect on the TG profile initiated with low tissue factor (0.2 pM). As expected, the addition of APC (2 nM, final) to NHP or HA plasma substantially reduced peak thrombin. However, GB5 dose-dependently increased peak thrombin in the presence of APC in NHP or HA plasma and restored TG to normal levels at ~20 nM. GB5 also protected FV from APC when assessed using a purified prothrombin activation assay. Western blotting experiments using FV proteolyzed with thrombin, APC, or plasmin revealed that GB5 binds the light chain A3-C1-C2. Preliminary experiments revealed that GB5 does not cross react with mouse FV. To evaluate the effect of GB5 in vivo, wild-type (WT) mice were treated with a liver targeted antisense oligonucleotide (ASO) to knockdown mouse plasma FV (ASO-FV; 40 mg/kg; FV-ASO mice). Mouse platelet FV was not impacted. To supplement the plasma compartment with FV, the FV-ASO mice were administered human FV (hFV-mice). This experimental set-up allowed for clot formation to largely be dependent on hFV using the mouse laser injury model. In these studies, we compared the kinetics of thrombus formation in WT mice, FV-ASO mice, or hFV-mice (n=2-3/group; 7-10 thrombi per group) for 10-15 minutes following laser injury. We found that platelet and fibrin accumulation was robust in WT mice and almost undetectable in FV-ASO mice (consistent with the lack of plasma FV), while clot formation was low but detectable in hFV-mice. There was no obvious difference in thrombus size when GB5 was given to WT or FV-ASO mice. However, in hFV-mice (200 μg/kg hFV), GB5 increased platelet and fibrin accumulation to levels seen with WT mice. Quantitative analysis revealed that compared to hFV mice alone, GB5 increased platelet accumulation 3-fold and fibrin (3-6-fold accumulation. Significantly greater accumulation of platelets and fibrin (~30-fold) was observed when higher amounts of hFV (400 μg/kg) were co-infused with GB5 compared to hFV-mice without antibody. Together, these results demonstrate that monoclonal antibody GB5 binds to hFV/FVa with high affinity and confers APC resistance. Using a unique mouse model to assess human FV, we found that GB5 enhanced clot formation in vivo using the laser injury model. From a mechanistic standpoint, these data show that protecting FV from APC translates to greater thrombin generation in vivo and suggest this approach may be useful to treat bleeding disorders such as HA and HB. Additional injury models using the hFV-mice and hemophilic mice to assess the effectiveness of GB5 are ongoing. Disclosures Crosby: Ionis Pharmaceuticals: Other: Jeffrey is a current employee of Ionis Pharmaceuticals. Revenko: Ionis Pharmaceuticals: Other: Alexey is a current employee of the company.. MacLeod: Ionis Pharmaceuticals: Other: Robert is a current employee of the company. Monia: Ionis Pharmaceuticals: Other: Brett is a current employee of the company. .
30
Brachet, Julien, Victoria L. Klinkert, Cory Rodgers, Robtel Neajai Pailey, Elieth Eyebiyi, Rachel Benchekroun, Grzegorz Micek, et al. "Book Reviews." Migration and Society 3, no. 1 (June 1, 2020): 316–34. http://dx.doi.org/10.3167/arms.2020.030130.
Full textAbstract:
NO GO WORLD: How Fear Is Redrawing Our Maps and Infecting Our Politics. Ruben Andersson. 2019. Berkeley: University of California Press. 360 pages. ISBN: 9780520294608.THE ROUTLEDGE HANDBOOK OF SOUTH-SOUTH RELATIONS. Elena Fiddian-Qasmiyeh, and Patricia Daley, eds. 2019. Abingdon, UK: Routledge. 448 pages. ISBN: 9781315624495.LITTLE MOGADISHU: Eastleigh, Nairobi’s Global Somali Hub. Neil Carrier. 2016. London: Hurst and Company. 313 pages. ISBN: 9781849044752.COMPARATIVE REVIEW: Call and Response Conversations on Race, Racism, and White Supremacy.WHY I’M NO LONGER TALKING TO WHITE PEOPLE ABOUT RACE. Reni Eddo-Lodge. 2017. London: Bloomsbury. 288 pages. ISBN: 9781408870587.WHITE FRAGILITY: Why It’s So Hard for White People to Talk about Racism. Robin DiAngelo. 2018. Boston: Beacon Press Books. 168 pages. ISBN: 9780807047415.AMOURS PRAGMATIQUES: Familles, migrations et sexualité au Cap-Vert aujourd’hui. Pierre-Joseph Laurent. 2018. Paris: Karthala. 456 pages. ISBN: 9782811119379 (hardback).HOME-LAND: Romanian Roma, Domestic Spaces and the State. Rachel Humphris. 2019. Bristol: Bristol University Press. 256 pages. ISBN: 9781529201925 (hardback).HANDBOOK ON THE GEOGRAPHIES OF GLOBALIZATION. Robert C. Kloosterman, Virginie Mamadouh, and Pieter Terhorst, eds. 2018. Amsterdam: Edward Elgar Publishing. 480 pages. ISBN: 9781785363832 (hardback).FROM HERE AND THERE: Diaspora Policies, Integration, and Social Rights Beyond Borders. Alexandra Délano Alonso. 2018. Oxford: Oxford University Press. 256 pages. ISBN: 9780190688585.LGBTI ASYLUM SEEKERS AND REFUGEES FROM A LEGAL AND POLITICAL PERSPECTIVE: Persecution, Asylum and Integration. Arzu Güler, Maryna Shevtsova, and Denise Venturi, eds. 2018. Cham, Switzerland: Springer. 354 pages. ISBN: 9783319919041 (hardback); ISBN: 9783319919058 (ebook).NEW BORDERS: Hotspots and the European Migration Regime. Antonis Vradis, Evie Papada, Joe Painter, and Anna Papoutsi. 2018. London: Pluto Press. 144 pages. ISBN: 9780745338460 (hardback); ISBN: 9780745338453 (paperback).ETHNOMORALITY OF CARE: Migrants and Their Aging Parents. Agnieszka Radziwinowiczówna, Anna Rosińska, and Weronika Kloc-Nowak. 2018. London: Routledge. 205 pages. ISBN: 9780815354031 (hardback); ISBN: 9781351134231 (ebook).
31
Duan, Maosheng, and Leo A. Paquette. "Enantioselective Total Synthesis of the Cyclophilin-Binding Immunosuppressive Agent Sanglifehrin A This work was financially supported by Eli Lilly and Company and a Robert Mayer Graduate Fellowship (to M.D.). We thank Prof. K. C. Nicolaou for providing authentic spectra of 1." Angewandte Chemie International Edition 40, no. 19 (October 1, 2001): 3632. http://dx.doi.org/10.1002/1521-3773(20011001)40:19<3632::aid-anie3632>3.0.co;2-5.
Full text
32
KITLV, Redactie. "Book Reviews." New West Indian Guide / Nieuwe West-Indische Gids 61, no. 1-2 (January 1, 1987): 55–114. http://dx.doi.org/10.1163/13822373-90002056.
Full textAbstract:
-Sidney W. Mintz, Mats Lundahl, The Haitian economy: man, land and markets. New York: St. Martins Press, 1983. 290 pp.-Regine Altagrace Latortue, Léon-Francois Hoffmann, Essays on Haitian Literature. Washington D.C.: Three Continents Press, 1984. 184 pp.-Robert Forster, Lieutenant Howard, The Haitian journal of lieutenant Howard, York Hussars, 1796-1798. Edited with an introduction by Roger Norman Buckley. Knoxville: University of Tennessee Press, 1985. liv + 194.-David Bray, Bernardo Vega, Los Estados Unidos y Trujillo, año 1930. Santo Domingo: Fundación Cultural Dominicano, 1986. 2 vols. xi + 1120 pp.-David Bray, Bernardo Vega, Los Estados Unidos y Trujillo, año 1947. Santo Domingo: Fundación Cultural Dominicana, 1984. 2 vols. xi + 1018 pp.-David Bray, Bernardo Vega, Nazismo, fascismo y falangismo en la Republica Dominicana. Santo Domingo: Fundación Cultural Dominicana, 1985. 415 pp.-Tony Thorndike, Bruce J. Calder, The impact of intervention: The Dominican Republic during the US occupation of 1916-1924. Austin: University of Texas Press, 1984. 358 pp.-Marcella M. Little, Jacques Barbier ,The North American role in the Spanish imperial economy 1760-1819. Manchester, England, 1984: Manchester University Press. pp. 232., Allan J. Kuethe (eds)-Janette Forte, Peter Riviere, Individual and society in Guiana: a comparative study of Amerindian social organisation. Cambridge, London, New York: Cambridge University Press, 1984. 127 pp.-Stephen D. Glazier, Jay D. Dobbin, The Jombee dance of Montserrat: a study of trance ritual in the West Indies. Columbus: Ohio State University Press, 1986. 202 pp.-Robert J. Stewart, Stephen D. Glazier, Marchin' the Pilgrims home: leadership and decision-making in an Afro-Caribbean faith. Connecticut and London: Greenwood Press, 1983. xv + 165 pp.-Sidney M. Greenfield, Karen Fog Olwig, Cultural adaptation and resistance on St. John: three centuries of Afro-Caribbean life. Gainesville: University of Florida Press, 1985. xii + 226 pp.-Adam Kendon, William Washabaugh, Five fingers for survival. Ann Arbor: Karoma Publishers, Inc., 1986. xiv + 198 pp.-Evelyne T. Menard, Carnot (F. Moloen), Alors ma chére...Propos d'un musicien guadeloupéen recueillis et traduits par Marie-Céline Lafontaine. Paris: Editions Caribéennes, 1986. 159 pp.-Sally Price, Suzanne Slesin ,Caribbean style. Authors include Daniel Rozensztroch. Photographs by Gilles de Chabaneix. New York: Clarkson N. Potter, 1985. 290 pp., Stafford Cliff, Jack Berthelot (eds)-Allison Blakely, Gert Oostindie ,In het land van de overheerser. Deel II. Antillianen en Surinamers in Nederland, 1634/1667-1954. Dordrecht (Holland) and Providence RI (U.S.A.): Foris Publications, 1986. xi + 255 pp., Emy Maduro (eds)-Rosemarijn Hoefte, E. van de Boogaart ,Overzee: Nederlandse koloniale geschiedenis, 1590-1975. Haarlem: Fibula-van Dishoek, 1982. 291 pp., P.J. Drooglever et al (eds)-Frederick J. Conway, P.I. Gomes, Rural development in the Caribbean. London: C. Hurst and Company. New York: St. Martins Press, 1985. xxi + 246 pp.-Steve M. Slaby, Charles Edquist, Capitalism, socialism and technology: a comparative study of Cuba and Jamaica. London: Zed Books Ltd., 1985. xiii + 182 pp.-Joan D. Mandle, June Nash ,Women and social change in Latin America. South Hadley, Mass.: Bergin and Garvey Publishers, 1986. 372 pp., Helen Safa (eds)-Bonham C. Richardson, Michael L. Conniff, Black labor on a white canal: Panama, 1904-1981. Pittsburgh, Pa.: University of Pittsburgh Press, 1985. xv + 221 pp.-Brackette F. Williams, Stephen Glazier, Caribbean ethnicity revisited. A special edition of Ethnic Groups, International periodical of ethnic studies. New York, London, Paris, Montreaux, Tokyo: Gordon Breach Science Publishers, 1985. 164 pp.-Gert J. Oostindie, Frauke Gewecke, Die Karibik; zur Geschichte, Politik und Kultur einer Region. Frankfurt/M: Verlag Klaus Dieter Vervuert 1984. 165 pp.
33
Amanah, Fitri, Sobrotul Imtikhanah, Fadli Hudaya, Nur Kholidah, and Musfirah Majid. "PENGARUH GOOD CORPORATE GOVERNANCE DAN COMPANY GROWTH TERHADAP KINERJA KEUANGAN DI BANK BRI SYARIAH INDONESIA PERIODE 2009 – 2018." Neraca 19, no. 2 (December 1, 2023): 104–19. http://dx.doi.org/10.48144/neraca.v19i2.1689.
Full textAbstract:
This study aims to examine the effect of Good Corporate Governance and Company Growth on Financial Performance at BRI Syariah Indonesia in 2009-2018. The independent variables used are Board of Commissioners Size, Audit Committee Size, Sharia Supervisory Board Size and Company Growth, the dependent variable used in this study is Return On Equity (ROE) at BRI Syariah Bank. This research is a quantitative study using SPSS version 16.0 and Microsoft Excel. In this study using a population of 13 Sharia Commercial Banks in Indonesia in 2009 - 2018. While the sample is 1 Sharia Commercial Bank, namely BRI Sharia Banks in 2009 - 2018, so that the total sample is 10, with a purposive sampling method in which the total sample used in the study this is as much as 10 annual reports of Islamic banks. Data analysis techniques used in this study with the classical assumption test, and hypothesis testing with multiple linear regression methods. The results showed that the size of the board of commissioners, the size of the audit committee, the size of the sharia supervisory board and company growth did not have a significant effect on Return On Equity (ROE). REFERENSI Amalia Rizky, 2014. “Pengaruh Penerapan GCG Terhadap Profitabilitas Bank Umum Syariah di Indonesia tahun 2010 -2013”. UIN Syarif Hidayatul Jakarta. Bank Indonesia. 2015. ”Statistik Perbankan Syariah (Islamic Banking Statistics) Mei 2015” (online). http://www.bi.go.id. Diakses tanggal 15 Desember 2019. Bank Indonesia www.bi.go.id Bank BRI Syariah, “Laporan Tahunan Bank BRI Syariah 2009-2018”, Dalil surat at-taubah.”Tentang Kinerja”. https://brainly.co.id/tugas/307251,diakses pada 8 maret 2020 Dalil surat at-taubah.”Tentang Kinerja”.https://brainly.co.id/tugas/646278,diakses pada 8 maret 2020 Dewan Syariah Nasional (DSN). 2003. Himpunan Fatwa Dewan Syariah Nasional. Jakarta. Ghozali, Imam. 2006. “Apilkasi Analisis Multivariate Dengan Program SPSS”. Undip, Semarang. Hasanah Nur, 2013. “Analisis Pengaruh Mekanisme Good Corporate Governance terhadap Kinerja Perbankan”. UIN Salatiga. Hidayah Nurul, 2013.” Pengaruh Corporate Social Responsibility, Leverage, Growth, Size terhadap ROE pada perusahaan LQ 45 yang tercatat di bursa efek Indonesia tahun 2009 – 2012”. IAIN Samarinda. Karina, 2018. “Pengaruh Good Corporate Governance terhadap kinerja keuangan di bank umum syariah tahun 2013-2015”.IAIN Surakarta. Kholidah, N., Hakim, M. R., & Purwanto, E. (2019). Analisis Kinerja Reksadana Saham Syariah Dengan Metode Sharpe, Treynor, Jensen, M², dan TT. Indonesian Interdisciplinary Journal of Sharia Economics (IIJSE), 1(2), 29-40. Lustyaningsih Fitri, 2015. “Pengaruh Intelektual Capital ,Rate of Growth of Intelectual Capital (ROGIC) dan Kualitas Penerapan GCG terhadap Kinerja Keuangan Bank Umum Syariah di Indonesia Periode 2010 – 2014”. UIN Syarif Hidayatul Jakarta. Lutfiani, A. P., & Hidayah, R. (2022). ESG Performance and Ownership Structure on Cost of Capital and Research & Development Investment. Fokus Bisnis Media Pengkajian Manajemen dan Akuntansi, 21(1), 25-42. Marshall, Robert dan Miranda. “Kamus Populer Uang dan Bank”. Ladangpustaka dan Intimedia, Jakarta. Muhamad Fadel, 2017.”Analisis Pengaruh Penerapan Good Corporate Governance (GCG) Terhadap Kinerja Keuangan (Studi Kasus Bank Syariah Periode 2012-2016)”. UIN Sunan Kalijaga Yogyakarta. Pratiwi Angrum, 2016. “Pengaruh kualitas Penerapan Good Corporate Governance (GCG) terhadap Kinerja Keuangan pada Bank Umum Syariah di indonesia perode 2010-2015”. IAIN Samarinda. Ridwan, Muhammad. 2004. “Manajemen Baitul maal Wat Tamwil (BMT)”. UII Press, Yogyakarta. Ridwansyah, 2018.”Pengaruh Good Corporate Governance Terhadap Kinerja Maqasid Syariah Bank Syariah di Indonesia Periode 2014-2017”.UIN Syarif Hidayatullah Jakarta. Risgiyanti, R., & Hidayah, R. (2020). The role of workplace spirituality in reducing the negative impact of organizational cynicism on job performance. Jurnal Aplikasi Manajemen, 18(4), 692-703. Riswan, R., & Suyono, E. (2016). Corporate diversification: Destroying or increasing firm value? Empirical evidence from Indonesia. Corporate Ownership & Control. 14 (4). Rosanti, C. (2020). Faktor-Faktor yang Mempengaruhi Inovasi Produk Koperasi Jasa Keuangan Syariah Pada KJKS BTM Se Jawa Tengah. Jurnal Ilmiah Ekonomi Islam, 6(1), 8-13. Sina Ibnu, 2010. “Pengaruh Penerapan Good Corporate Governance terhadap Profitabilitas pada Perusahaan Go Public di Indonesia”.Universitas Indonesia. Sukandar Panky, 2014. “Pengaruh Ukuran Dewan Direksi dan Dewan Komisaris serta Ukuran Peusahaan terhadap Kinerja Keuangan perusahaan”. UIN Syarif Hidayatul Jakarta. Surat al-Baqarah ayat 28. “Tentang Akuntansi Syariah” https://www.dutaislam.com/2019/03/tafsir-surat-al-baqarah-ayat-282-dasar-akuntansi-islam.html, di akses pada tanggal 5 maret 2020. Tjondro David, 2011. “Pengaruh Good Cororate Governance (GCG) terhadap Profitabilitas dan Kinerja Perbankan yang tercatat di Bursa Efek Indonesia”. Universitas Diponegoro. Tunggal, A. W. (2010). “Pokok-Pokok Analisis Laporan Keuangan”. Jakarta: Harvarindo. Undang- Undang No. 10 Pasal 1 Tahun 1998 Tentang Perubahan Undang Undang No. 7 Tahun 1992 Tentang Perbankan. Undang-Undang RI Nomor 21 tahun 2008, “Tentang Perbankan Syariah”, http://www.hukumonline.com/pusatdata/detail/26940/node/70/uu-no-40-tahun-2007-perseroan-terbatas, di akses pada 15 Desember 2019. Wahyuningsih Panca, 2009.”Pengaruh Struktur Kepemilikan Institusional dan Corporate Governance Terhadap Manajemen Laba”. Dosen STIE Pelita Nusantara Semarang. www.brisyariah.co.id, di unduh 15 Desember 2019. Zaini, Z. 2014. “Memahami Bisnis Bank Syariah (Ikatan Bankir Indonesia)”. Jakarta: Pt. Gramedia Pustaka Utama.
34
Ertl, Rett. "Robert C. Tucker, Political Culture and Leadership in the Soviet Union From Lenin to Gorbachev. New York: W.W. Norton and Company, 1987. 214 pp. $22.50. - Anthony D'Agostino, Soviet Succession Struggles: Kremlinology and the Russian Question from Lenin to Gorbachev. Boston: Allen & Unwin, 1988. 274 pp. $45.00." Nationalities Papers 16, no. 2 (1988): 300–304. http://dx.doi.org/10.1017/s009059920001268x.
Full text
35
Kneeshaw, Stephen, Richard Harvey, D'Ann Campbell, Robert W. Dubay, John T. Reilly, James F. Marran, Ann W. Ellis, et al. "Book Reviews." Teaching History: A Journal of Methods 10, no. 2 (May 4, 2020): 82–96. http://dx.doi.org/10.33043/th.10.2.82-96.
Full textAbstract:
Robert William Fogel and G. R. Elton. Which Road to the Past? Two Views of History. New Haven and London: Yale University Press, 1983. Pp. vii, 136. Cloth, $14.95. Review by Stephen Kneeshaw of The School of the Ozarks. Emmanuel LeRoy Ladurie. The Mind and Method of the Historian. Translated by Sian Reynolds and Ben Reynolds. Chicago: University of Chicago Press, 1981. Pp. v, 310. Paper, $9.95. Review by Richard Harvey of Ohio University. John E. O'Connor, ed. American History/ American Television: Interpreting the Video Past. New York: Frederick Ungar Publishing Company, 1983. Pp. 463. Cloth, $17.50; Paper, $8.95. Review by D' Ann Campbell of Indiana University. Foster Rhea Dulles & Melvyn Dubofsky. Labor in America: A History. Arlington Heights, Illinois: Harlan Davidson, Inc., 1984. 4th edition. Pp. ix, 425. Cloth, $25.95. Paper, $15.95. Review by Robert W. Dubay of Bainbridge Junior College. Karen Ordahl Kupperman. Roanoke: The Abandoned Colony. Totowa, New Jersey: Rowman & Allanheld, 1984. Pp. viii, 182. Cloth, $24.95; Paper, $12.50. Review by John T. Reilly of Mount Saint Mary College. Kevin O'Reilly. Critical Thinking in American History: Exploration to Constitution. South Hamilton, Massachusetts: Hamilton-Wenham Regional High School, 1983. Pp. 86. Paper, $2.95. Teacher's Guides: Pp. 180. Paper, $12.95; Kevin O'Reilly. Critical Thinking in American History: New Republic to Civil War. South Hamilton, Massachusetts: Hamilton-Wenham Regional High School, 1984. Pp. 106. Paper, $2.95. Teacher's Guide: Pp. 190. Paper, $12.95. Review by James F. Marran of New Trier Township High School, Winnetka, Illinois. Michael J. Cassity, ed. Chains of Fear: American Race Relations Since Reconstruction. Westport, Connecticut: Greenwood Press, 1984. Pp. xxxv, 253. Cloth, $35.00. Review by Ann W. Ellis of Kennesaw College. L. P. Morris. Eastern Europe Since 1945. London and Exeter, New Hampshire: Heinemann Educational Books, 1984. Pp. 211. Paper, $10.00. Review by Thomas T. Lewis, Mount Senario College. John Marks. Science and the Making of the Modern World. Portsmouth, New Hampshire: Heinemann Educational Books, Inc., 1983. Pp. xii, 507. Paper, $25.00. Review by Howard A. Barnes of Winston-Salem State University. Kenneth G. Alfers, Cecil Larry Pool, William F. Mugleston, eds. American's Second Century: Topical Readings, 1865-Present. Dubuque, Iowa: Kendall/ Hunt Publishing Co., 1984. Pp. viii, 381. Paper, $8.95. Review by Richard D. Schubart of Phillips Exeter Academy. Sam C. Sarkesian. America's Forgotten Wars: The Counterrevoltuionary Past and Lessons for the Future. Westport, Connecticut: Greenwood Press, 1984. Pp. xiv, 265. Cloth, $29.95. Review by Richard Selcer of Mountain View College. Edward Wagenknecht. Daughters of the Covenant: Portraits of Six Jewish Women. Amherst: University of Massachusetts, 1983. Pp. viii, 192. Cloth, $17.50. Review by Abraham D. Kriegel of Memphis State University. Morton Borden. Jews, Turks, and Infidels. Chapel Hill and London: University of North Carolina Press, 1984. Pp. x, 163. Cloth, $17.95. Review by Raymond J. Jirran of Thomas Nelson Community College. Richard Schlatter, ed. Recent Views on British History: Essays on Historical Writing Since 1966. New Brunswick: Rutgers University Press, 1984. Pp. xiii, 524. Cloth, $50.00. Review by Fred R. van Hartesveldt of Fort Valley State College. Simon Hornblower. The Greek World, 479-323 B.C. London and New York: Methuen, 1983. Pp. xi, 354. Cloth, $24.00; Paper, $11.95. Review by Dan Levinson of Thayer Academy, Braintree, Massachusetts. H. R. Kedward. Resistance in Vichy France. New York: Oxford University Press, 1978. Paper edition 1983. Pp. ix, 311. Paper, $13.95. Review by Sanford J. Gutman of the State University of New York at Cortland.
36
Nackenoff, Carol. "Contested Terrain: Understanding the Persistence of Racial Inequality in AmericaThe Color of Politics: Race and the Mainsprings of American Politics. By Michael Goldfield Facing up to the American Dream. By Jennifer Hochschild Shifting the Color Line: Race and the American Welfare State. By Robert C. Lieberman Voting Hopes or Fears?. By Keith Reeves Reaching beyond Race. By Paul M. Sniderman and Edward G. Carmines." Polity 31, no. 4 (June 1999): 683–91. http://dx.doi.org/10.2307/3235243.
Full text
37
Hass, Charles N. "Taste and odor problems associated with chlorine dioxide by Andrea M. Dietrich and Robert C. Hoehm in Conjunction with the American Water Works Services Company, AWWA Research Foundation and American Water Works Association, Denver, Co, 148 pages [ISBN No.: 0-89967-578-2] U.S. List Price $31.50 (1991)." Environmental Progress 13, no. 1 (February 1994): F10—F11. http://dx.doi.org/10.1002/ep.670130107.
Full text
38
KITLV, Redactie. "Book reviews." Bijdragen tot de taal-, land- en volkenkunde / Journal of the Humanities and Social Sciences of Southeast Asia 165, no. 1 (2009): 129–89. http://dx.doi.org/10.1163/22134379-90003646.
Full textAbstract:
Johnny Tjia; A grammar of Mualang: An Ibanic language of West Kalimantan, Indonesia (Alexander Adelaar) Christopher Moseley (ed.); Encyclopedia of the world’s endangered languages (Peter K. Austin) Ian Rae and Morgen Witzel; The Overseas Chinese of South east Asia: History, culture, business (Chin Yee Whah) Ab Massier; The voice of the law in transition: Indonesian jurists and their languages, 1915-2000 (Dwi Noverini Djenar) Henk Schulte Nordholt and Gerry van Klinken (eds); Renegotiating boundaries: Local politics in post-Suharto Indonesia (Maribeth Erb) Nghia M. Vo; The Vietnamese boat people, 1954 and 1975-1992 (Martin Grossheim) O.W. Wolters; Early Southeast Asia: Selected essays [edited by Craig J. Reynolds] (Hans Hägerdal) Michael W. Scott; The severed snake: Matrilineages, making place, and a Melanesian Christianity in Southeast Solomon Islands (Menno Hekker) John H. McGlynn, Oscar Motuloh, Suzanne Charlé, Jeffrey Hadler, Bambang Bujono, Margaret Glade Agusta, and Gedsiri Suhartono; Indonesia in the Soeharto years: Issues, incidents and images (David Henley) Hanneke Hollander; Een man met een speurdersneus: Carel Groenevelt (1899-1973), beroepsverzamelaar voor Tropenmuseum en Wereldmuseum in Nieuw-Guinea (Anna-Karina Hermkens) Balk, G.L., F. van Dijk and D.J. Kortlang (with contributions by F.S. Gaastra, Hendrik E. Niemeijer and P. Koenders); The Archives of the Dutch East India Company (VOC) and the local institutions in Batavia (Jakarta) (Ton Kappelhof) Gusti Asnan; Memikir ulang regionalisme: Sumatera Barat tahun 1950-an (Gerry van Klinken) Lise Lavelle; Amerta Movement of Java 1986-1997: An Asian movement improvisation (Dick van der Meij) Nicole-Claude Mathieu (ed.); Une maison sans fille est une maison morte: La personne et le genre en sociétés matrilinéaires et/ou uxorilocales (Joke van Reenen) Henk Schulte Nordholt; Indonesië na Soeharto: Reformasi en restauratie (Elske Schouten) V.I. Braginsky; … and sails the boat downstream: Malay Sufi poems of the boat (Suryadi) Gilles Gravelle; Meyah: An east Bird’s Head language of Papua, Indonesia (Ian Tupper) Penny Edwards; Cambodge: The cultivation of a nation, 1860-1945 (Un Leang) J. Stephen Lansing; Perfect order: Recognizing complexity in Bali (Carol Warren) Roxana Waterson (ed.); Southeast Asian lives: Personal narratives and historical experience (C.W. Watson) Jean DeBernardi; The way that lives in the heart: Chinese popular religion and spirit mediums in Penang, Malaysia (Robert Wessing) REVIEW ESSAY Environmental and archaeological perspectives on Southeast Asia Peter Boomgaard; Southeast Asia: An environmental history Peter Boomgaard (ed.); A world of water: Rain, rivers and seas in Southeast Asian histories Ian Glover and Peter Bellwood (eds); Southeast Asia: From prehistory to history Avijit Gupta (ed.); The physical geography of Southeast Asia (Eric C. Thompson)
39
Pradana, Muhammad Erza. "What Drives Nuclear-Aspiring States? The Cases of Iran and North Korea." Jurnal Sentris 4, no. 1 (June 16, 2023): 61–72. http://dx.doi.org/10.26593/sentris.v4i1.6425.61-72.
Full textAbstract:
Why do states want to acquire nuclear weapons? In other words, what drives nuclear-aspiring states? This is the basic question that the author seeks to address in this research. To do so, this research will focus on two standout cases: Iran and North Korea. By employing structural realism as a tool of analysis, the author argues that it is the structure of the international system that drives both Iran and North Korea to acquire nuclear weapons of their own. Specifically, it is the highly unequal distribution of power both regionally and globally that encourages both states to go nuclear. At the global level, both Iran and North Korea found themselves in hostilities with a much more powerful state, the United States. The hostilities and the fact that the United States is way more powerful increase the fear of being attacked in both countries. Similarly, at the regional level, both states face neighbors that are relatively more powerful and have alliances with the United States. Thus, this imbalance of power and the fear it created in both Iran and North Korea give them great incentive to go nuclear, as nuclear weapons would act as a deterrent against any possible aggression. This research is qualitative and based on the literature study data collection method. Keywords: Nuclear proliferation; national security; distribution of capabilities; structural realism REFERENCES Abulof, Uriel. 2014. "Revisiting Iran’s nuclear rationales." International Politics 51(3), 404-415. Albright, David, and Andrea Stricker. 2010. "Iran’s Nuclear Program." In The Iran Primer: Power, Politics, and US Policy, edited by Robin Wright, 77-81. Washington, D.C.: United States Institute of Peace Pres. Bowen, W.Q., and J. Brewer. 2011. "Iran’s nuclear challenge: Nine years and counting." International Affairs 87(4): 923–943. Chubin, S. 2007. "Iran: Domestic politics and nuclear choices." In Strategic Asia 2007–08: Domestic Political Change and Grand Strategy, edited by A.J. Tellis, M. Wills and N. Bisley, 301–340. Washington DC: National Bureau of Asian Research. Cronin, Patrick M. 2008. "The Trouble with North Korea." In Double Trouble: Iran and North Korea as Challenges to International Security, edited by Patrick M. Cronin, 79-89. Wesport: Praeger Security International Buszynski, Leszek. 2021. "North Korea's Nuclear Diplomacy." In Routledge Handbook of Contemporary North Korea, edited by Adrian Buzo, -170. Oxon: Routledge. Donnelly, Jack. 2005. "Realism." In Theories of International Relations, edited by Scott Burchill, Andrew Linklater, Richard Devetak, Jack Donnelly, Christian Reus-Smit Matthew Paterson and Jacqui True, 29-54. Basingstoke: Palgrave Macmillan. Greitens, Sheena Chestnut. 2020. "Proliferation of weapons of mass destruction." In The Globalization of World Politics: An Introduction to International Relations, by John Baylis, Steve Smith and Patricia Owens, 465-480. Oxford: Oxford University. Hobbs, Christopher, and Matthew Moran. 2014. Exploring Regional Responses to a Nuclear Iran. Basingstoke: Palgrave Macmillan. Ikenberry, G. John, Michael Mastanduno, and William C. Wohlforth. 2011. "Introduction: unipolarity, state, and systemic consequenses." In International relations theory and the consequences of unipolarity, edited by G. John Ikenberry, Michael Mastanduno and William C. Wohlforth, 1-32. Cambridge: Cambridge University Press. Jackson, Robert, and Georg Sørensen. 2013. Introduction to International Relations: Theories and Approaches. Oxford: Oxford University Press. Jackson, Van. 2018. On the Brink: Trump, Kim, and the Threat of Nuclear War. Cambridge: Cambridge University Press. Jørgensen, Knud Erik. 2018. International Relations Theory: A New Introduction. London: Palgrave. Kaufman, Joyce P. 2021. A Concise History of U.S. Foreign Policy. Lanham, Maryland: Rowman & Littlefield Krauthammer, Charles. 1990. "The Unipolar Moment." Foreign Affairs 70(1), 23-33. Mærli, Morten Bremer, and Sverre Lodgaard. 2007. "Introduction." In Nuclear Proliferation and International Security, edited by Morten Bremer Mærli and Sverre Lodgaard, 1-5. Oxon: Routledge. Mearsheimer, John J. 2018. The Great Delusion: Liberal Dreams and International Realities. New Haven: Yale University Press. —. 2001. The Tragedy of Great Power Politics. New York: WW Norton & Company. Mearsheimer, John J., and Stephen M. Walt. 2007. The Israel Lobby and US Foreign Policy. New York: Farrar, Straus and Giroux. Pollack, Jonathan D. 2011. No Exit: North Korea, Nuclear Weapons and International Security. New York: Routledge. Popoola, Michael Akin, Deborah Ebunoluwa Oluwadara, and Abiodun A. Adesegun. 2019. "North Korea Nucler Proliferation in the Context of the Realist Theory: A Review." European Journal of Social Sciences 58(1), 75-82. Porter, Patrick. 2015. The Global Village Myth: Distance, War and the Limits of Power. Washington, D.C.: Georgetown University Press. Sharma, Anu. 2022. Through the Looking Glass: Iran and Its Foreign Relations. New York: Routledge Smith, Shane. 2021. "Nuclear Weapons and North Korean Foreign Policy." In Routledge Handbook of Contemporary North Korea, edited by Adrian Buzo, 141-154. Oxon: Routledge. Tagma, Halit M. E. 2020. "Realism and Iran’s Nuclear Program." In Understanding and Explaining the Iranian Nuclear 'Crisis', by Halit M. E. Tagma and Paul E. Lenze Jr., 65-103. Lanham: Lexington Books. Tagma, Halit M.E, and Paul E. Lenze Jr. Understanding and Explaining the Iranian Nuclear 'Crisis'. Lanham: Lexington Books, 2020. Taylor, Steven J., Robert Bogdan, and Marjorie L. DeVault. 2016. Introduction to Qualitative Research Methods: A Guidebook and Resource. New Jersey: John Wiley & Sons, Inc. Thomas, Garth. 2017. " Realism And Its Impact To The North Korean, South Korean, And Chinese Nuclear Programs (." Master's Thesis. Baltimore, Maryland: Johns Hopkins University, August. Accessed June 27, 2022. https://jscholarship.library.jhu.edu/bitstream/handle/1774.2/60434/THOMAS-THESIS 2017.pdf?sequence=1&isAllowed=y. Viotti, Paul R., and Mark V. Kauppi. 2012. International Relations Theory. Boston: Longman. Vromen, Ariadne. 2010. "Debating Methods: Rediscovering Qualitative Approaches." In Theory and Methods in Political Science, edited by David Marsh and Gerry Stoker, 249-266. Basingstoke: Palgrave Macmillan. Waltz, Kenneth N. 1979. Theory of International Politics. Reading: Addison-Wesley Publishing Company, Inc. Waltz, Kenneth. 2000. "Structural Realism after the Cold War ." International Security 25(1), pp. 5– 41. Yonhap News Agency. 2018. N. Korea will not give up nuclear weapons: Mearsheimer . March 20. Accessed May 18, 2023. https://en.yna.co.kr/view/AEN20180320010200315.
40
Sims, Robert C., Darlene E. Fisher, Steven A. Leibo, Pasquale E. Micciche, Fred R. Van Hartesveldt, W. Benjamin Kennedy, C. Ashley Ellefson, et al. "Book Reviews." Teaching History: A Journal of Methods 13, no. 2 (May 5, 1988): 80–104. http://dx.doi.org/10.33043/th.13.2.80-104.
Full textAbstract:
Michael B. Katz. Reconstructing American Education. Cambridge and London: Harvard University Press, 1987. Pp. viii, 212. Cloth, $22.50; E. D. Hirsch, Jr. Cultural Literacy: What Every American Needs to Know. Boston: Houghton Mifflin Co., 1987. Pp. xvii, 251. Cloth, $16.45; Diana Ravitch and Chester E. Finn, Jr. What Do Our 17-Year-Olds Know? A Report on the First National Assessment of History and Literature. New York: Harper & Row, 1987. Pp. ix, 293. Cloth, $15.95. Review by Richard A. Diem of The University of Texas at San Antonio. Henry J. Steffens and Mary Jane Dickerson. Writer's Guide: History. Lexington, Massachusetts, and Toronto: D. C. Heath and Company, 1987. Pp. x, 211. Paper, $6.95. Review by William G. Wraga of Bernards Township Public Schools, Basking Ridge, New Jersey. J. Kelley Sowards, ed. Makers of the Western Tradition: Portraits from History. New York: St. Martin's Press, 1987. Fourth edition. Vol: 1: Pp. ix, 306. Paper, $12.70. Vol. 2: Pp. ix, 325. Paper, $12.70. Review by Robert B. Luehrs of Fort Hays State University. John L. Beatty and Oliver A. Johnson, eds. Heritage of Western Civilization. Englewood Cliffs, New Jersey: Prentice-Hall, Inc., 1987. Sixth Edition. Volume I: Pp. xi, 465. Paper, $16.00; Volume II: pp. xi, 404. Paper, $16.00. Review by Dav Levinson of Thayer Academy, Braintree, Massachusetts. Lynn H. Nelson, ed. The Human Perspective: Readings in World Civilization. New York: Harcourt Brace Jovanovich, 1987. Vol. I: The Ancient World to the Early Modern Era. Pp. viii, 328. Paper, $10.50. Vol. II: The Modern World Through the Twentieth Century. Pp, x, 386. Paper, 10.50. Review by Gerald H. Davis of Georgia State University. Gerald N. Grob and George Attan Billias, eds. Interpretations of American History: Patterns and Perspectives. New York: The Free Press, 1987. Fifth Edition. Volume I: Pp. xi, 499. Paper, $20.00: Volume II: Pp. ix, 502. Paper, $20.00. Review by Larry Madaras of Howard Community College. Eugene Kuzirian and Larry Madaras, eds. Taking Sides: Clashing Views on Controversial Issues in American History. -- Volume II: Reconstruction to the Present. Guilford, Connecticut: The Dushkin Publishing Groups, Inc., 1987. Pp. xii, 384. Paper, $9.50. Review by James F. Adomanis of Anne Arundel County Public Schools, Annapolis, Maryland. Joann P. Krieg, ed. To Know the Place: Teaching Local History. Hempstead, New York: Hofstra University Long Island Studies Institute, 1986. Pp. 30. Paper, $4.95. Review by Marilyn E. Weigold of Pace University. Roger Lane. Roots of Violence in Black Philadelphia, 1860-1900. Cambridge, Massachusetts, and London: Harvard University Press, 1986. Pp. 213. Cloth, $25.00. Review by Ronald E. Butchart of SUNY College at Cortland. Pete Daniel. Breaking the Land: The Transformation of Cotton, Tobacco, and Rice Cultures since 1880. Urbana and Chicago: University of Illinois Press, 1985. Pp. xvi, 352. Paper, $22.50. Review by Thomas S. Isern of Emporia State University. Norman L. Rosenberg and Emily S. Rosenberg. In Our Times: America Since World War II. Englewood Cliffs, New Jersey: Prentice-Hall, 1987. Third edition. Pp. xi, 316. Paper, $20.00; William H. Chafe and Harvard Sitkoff, eds. A History of Our Time: Readings on Postwar America. New York: Oxford University Press, 1987. Second edition. Pp. xiii, 453. Paper, $12.95. Review by Monroe Billington of New Mexico State University. Frank W. Porter III, ed. Strategies for Survival: American Indians in the Eastern United States. New York, Westport, Connecticut, and London: Greenwood Press, 1986. Pp. xvi, 232. Cloth, $35.00. Review by Richard Robertson of St. Charles County Community College. Kevin Sharpe, ed. Faction & Parliament: Essays on Early Stuart History. London and New York: Methuen, 1985. Pp. xvii, 292. Paper, $13.95; Derek Hirst. Authority and Conflict: England, 1603-1658. Cambridge: Harvard University Press, 1986. Pp. viii, 390. Cloth, $35.00. Review by K. Gird Romer of Kennesaw College. N. F. R. Crafts. British Economic Growth During the Industrial Revolution. New York: Oxford University Press, 1985. Pp. 193. Paper, $11.95; Maxine Berg. The Age of Manufactures, 1700-1820. New York: Oxford University Press, 1985. Pp. 378. Paper, $10.95. Review by C. Ashley Ellefson of SUNY College at Cortland. J. M. Thompson. The French Revolution. New York: Basil Blackwell, 1985 reissue. Pp. xvi, 544. Cloth, $45.00; Paper, $12.95. Review by W. Benjamin Kennedy of West Georgia College. J. P. T. Bury. France, 1814-1940. London and New York: Methuen, 1985. Fifth edition. Pp. viii, 288. Paper, $13.95; Roger Magraw. France, 1815-1914: The Bourgeois Century. New York and Oxford: Oxford University Press, 1985. Pp. 375. Cloth, $24.95; Paper, $9.95; D. M.G. Sutherland. France, 1789-1815: Revolution and Counterrevolution. New York and Oxford: Oxford University Press, 1986. Pp. 242. Cloth, $32.50; Paper, $12.95. Review by Fred R. van Hartesveldt of Fort Valley State College. Woodford McClellan. Russia: A History of the Soviet Period. Englewood Cliffs, New Jersey: Prentice-Hall, 1986. Pp. xi, 387. Paper, $23.95. Review by Pasquale E. Micciche of Fitchburg State College. Ranbir Vohra. China's Path to Modernization: A Historical Review from 1800 to the Present. Englewood Cliffs, New Jersey: Prentice-Hall, 1987. Pp. xiii, 302. Paper, $22.95. Reivew by Steven A. Leibo of Russell Sage College. John King Fairbank. China Watch. Cambridge and London: Harvard University Press, 1987. Pp. viii, Cloth, $20.00. Review by Darlene E. Fisher of New Trier Township High School, Winnetka, Illinois. Ronald Takaki, ed. From Different Shores: Perspectives on Race and Ethnicity in America. New York and Oxford: Oxford University Press, 1987. Pp. 253. Paper, $13.95. Review by Robert C. Sims of Boise State University.
41
Tillett, W., A. Egeberg, E. Sonkoly, P. Gorecki, A. Tjärnlund, J. Buyze, S. Wegner, and D. Mcgonagle. "POS1033 DYNAMICS OF NAIL PSORIASIS WITH GUSELKUMAB TREATMENT AND WITHDRAWAL IN ASSOCIATION WITH SKIN RESPONSE AND PATIENT-REPORTED OUTCOMES: A POST HOC ANALYSIS OF THE VOYAGE 2 PHASE 3 TRIAL." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 830. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1478.
Full textAbstract:
BackgroundNail psoriasis can be difficult to treat, affects ~50% of patients with psoriasis and can involve the nail matrix (pitting, leukonychia) and/or nail bed (onycholysis, splinter haemorrhages). Evidence suggests nail psoriasis may be associated with risk of developing psoriatic arthritis, in particular distal interphalangeal joint erosion.1–3 Data to Week (Wk) 24 from VOYAGE 1 and 2, two Phase 3 clinical trials, indicate that the anti-interleukin-23 monoclonal antibody guselkumab (GUS) is more effective than placebo and as effective as adalimumab in treating nail psoriasis.4 Furthermore, GUS is also associated with maintained Psoriasis Area and Severity Index (PASI) following treatment withdrawal in VOYAGE 2; however, nail response is not as well understood in this context.5ObjectivesThis VOYAGE 2 post hoc analysis evaluated nail response and its association with skin response and patient-reported outcomes (PROs) in two groups, one experiencing GUS withdrawal and the other receiving continuous GUS.MethodsPatients had moderate-to-severe plaque psoriasis and nail psoriasis, were initially randomised to GUS, and achieved PASI 90 at Wk 28. Patients were then re-randomised to placebo (GUS withdrawal) or GUS every 8 wks (GUS continuation). Nail Psoriasis Severity Index (NAPSI; grading the most affected nail), fingernail Physician’s Global Assessment (f-PGA), PASI and Dermatology Life Quality Index (DLQI) are reported as observed at Wk 0, 16, 24 and 48.ResultsAmong 209 patients, NAPSI, f-PGA, PASI and DLQI showed similar trends in both groups until Wk 24. All endpoints improved from baseline; and at Wk 24, patients in the GUS withdrawal and GUS continuation groups achieved a mean NAPSI of 1.7 and 1.8 (nail matrix 1.0 and 1.0; nail bed 0.7 and 0.8); f-PGA 0.9 and 0.9; PASI 0.6 and 0.6; and DLQI 2.2 and 2.3, respectively (Table 1). Nail changes continued to follow skin trends through Wk 48 (Figure 1); with GUS withdrawal, worsening of PASI and DLQI was proportionally greater than that of NAPSI and f-PGA; with GUS continuation, PASI and DLQI remained fairly stable, and NAPSI and f-PGA continued to improve. Nails were numerically slower to respond to GUS initiation and withdrawal than skin, with a more pronounced delay for nail matrix vs nail bed. In patients who sustained a PASI 90 response at Wk 48, despite GUS withdrawal, a high level of nail response was also maintained.Table 1.NAPSI, f-PGA, PASI and DLQI through Wk 48 in GUS withdrawal and GUS continuation groupsWk 0Wk 16Wk 24Wk 28Wk 48GUS withdrawal*GUSRPlacebon97969696NAPSI5.0 (2.1)2.5 (1.9)1.7 (1.9)1.9 (2.1)Nail matrix2.7 (1.3)1.5 (1.3)1.0 (1.2)0.9 (1.3)Nail bed2.2 (1.2)0.9 (1.0)0.7 (1.0)1.0 (1.1)n98979797f-PGA2.5 (0.8)1.3 (0.9)0.9 (0.8)1.1 (1.0)n101101100100PASI23.1 (9.0)1.3 (2.7)0.6 (1.4)5.2 (6.1)n101101100100DLQI14.5 (6.1)2.8 (4.1)2.2 (3.6)7.0 (7.4)GUS continuationGUSRGUSn108106107105NAPSI4.4 (1.8)2.4 (2.2)1.8 (2.0)1.2 (1.6)Nail matrix2.5 (1.2)†1.4 (1.3)1.0 (1.2)0.7 (1.0)Nail bed1.9 (1.2)1.0 (1.1)0.8 (1.0)0.5 (0.8)n108106107105f-PGA2.4 (0.9)1.1 (0.9)0.9 (0.9)0.7 (0.8)n108108108106PASI22.6 (8.8)1.2 (2.1)0.6 (1.1)1.3 (3.5)n107108108104DLQI14.3 (6.4)2.9 (4.2)2.3 (4.0)1.8 (3.4)Data are mean (standard deviation). *n=10 reinitiated GUS upon loss of 50% of Wk 28 PASI 90(at n=1 Wk 36, n=2 Wk 40, n=7 Wk 44); †n=107; R, re-randomisation of PASI 90 responders.ConclusionGUS treatment through Wk 48 improved nail psoriasis, skin psoriasis and PROs. When GUS was withdrawn, loss of response was slower in nails vs skin. These findings support that nail outcomes follow skin outcome trends with GUS treatment and that nail outcomes should contribute to evaluation of treatment efficacy and disease progression.2,3,6References[1]Robert B. Dermatology 2010; 221 Suppl 1: 1–5;[2]Antony A et al. J Rheumatol 2019; 46: 1097–102.[3]Wilson F et al. Arthritis Rheum 2009; 61: 233–39;[4]Foley P et al. JAMA Dermatol 2018; 154: 676–83;[5]Conrad C et al. AAD 2021. P26573.[6]Conrad C et al. Dermatol Ther 2022; 12: 233–41.AcknowledgementsThis analysis was funded by Janssen and medical writing support was provided by OPEN Health Medical Communications.Disclosure of InterestsWilliam Tillett Speakers bureau: Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Consultant of: Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Alexander Egeberg Speakers bureau: AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and JanssenPharmaceuticals, Consultant of: AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and JanssenPharmaceuticals, Grant/research support from: Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, Enikö Sonkoly Speakers bureau: AbbVie, Eli Lilly, UCB, Janssen, Novartis, Sanofi and LEO Pharma, Grant/research support from: Pfizer, Patricia Gorecki Employee of: Janssen, Anna Tjärnlund Employee of: Janssen, Jozefien Buyze Employee of: Janssen, Sven Wegner Employee of: Janssen, Dennis McGonagle Speakers bureau: Abbvie, BMS, Celgene, Janssen, Novartis, Lilly, UCB, Grant/research support from: Abbvie, BMS, Celgene, Janssen, Novartis, Lilly, UCB
42
JPT staff, _. "SPE Board Announces Nominees for 2024 President and 2023 Directors." Journal of Petroleum Technology 74, no. 07 (July 1, 2022): 39–42. http://dx.doi.org/10.2118/0722-0039-jpt.
Full textAbstract:
2024 SPE President Terry Palisch is the vice president of technology and engineering at CARBO Ceramics in Richardson, Texas. He began his career with ARCO, during which he served 4 years in Algeria and 10 years as a senior petroleum engineer in Alaska. Palisch joined CARBO in 2004 and in his current position leads a team of technologists developing and championing new products and services and advising clients on completion and fracture optimization. Palisch has been an active SPE member serving in various roles, including past chairman of the SPE Dallas Section, past chair of the SPE Annual Technical Conference and Exhibition (ATCE) technical program and former SPE Completions Technical Director. He is an SPE Distinguished Member and received the award for Distinguished Service, as well as the SPE Mid‑Continent Regional Completions Optimization and Technology Award and the Regional Service Award. In 2013, he was named one of the Top 15 Best Engineers by the Texas Independent Producers and Royalty Owners Association, and in 2015 he was named the SPE Dallas Section Engineer of the Year. He has authored more than 50 SPE technical papers and holds several patents. Palisch holds a bachelor’s degree in petroleum engineering from University of Missouri‑Rolla (now Missouri University of Science and Technology) and was recently recognized as a Distinguished Alumnus. North America Regional Director Robert C. Martinez is president and CEO of Titan Rock Exploration & Production and president of Alpine Gas. He has more than 23 years of experience developing and optimizing oil and gas assets throughout the US, including conventional assets, unconventional horizontal development programs, and enhanced oil recovery projects. Middle East and North Africa Regional Director Mohamed Al Marzouqi is senior vice president of development at ADNOC Upstream Directorate. He has been with ADNOC since 2005. He joined ZADCO (ADNOC Offshore) as a petroleum engineer in field development to head the maximum-reservoir- contact (MRC) well-design team during which first production began through MRC wells from an artificial island. As a senior manager for reservoir development at ZADCO, he developed reservoir management strategy to redevelop a multibillion-dollar project in the Upper Zakum field through artificial islands. He led the team in the development of integrated reservoir management for ADNOC Group. Drilling Technical Director Robin Macmillan is the chief sales officer at Data Gumbo. He was previously senior vice president for business development at NOV, manager of Schlumberger drilling and measurements in Canada, and president at drill-bit company ReedHycalog. In his early career he worked in offshore and onshore drilling operations in several countries across North and Latin America, Africa, the Middle East, and Europe. He is the current vice president of drilling services and a member of the Executive Committee at the International Association of Drilling Contractors, where he is also Chair Emeritus of the Advanced Rig Technology Committee and a member of the Drilling Engineering Committee. Health, Safety, Environment, and Sustainability Technical Director Susan (Sue) Staley is the sustainability director for vPSI Group LLC where she leads the company’s sustainability practice. Prior to joining vPSI, she was the general manager of soil and groundwater technology at Shell and held various positions there during her 18-year tenure. Prior to Shell, she worked as a consultant at ERM. Staley has been an environmental and safety engineer for 30 years.
43
Li, Pengxiang, Vrushabh P. Ladage, Jianbin Mao, Girish Prajapati, Dovie L. Watson, Robert Gross, and Jalpa A. Doshi. "823. Characteristics, Comorbidities, and Medication Burden among People Living with HIV in the U.S. Medicare Program." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S504. http://dx.doi.org/10.1093/ofid/ofab466.1019.
Full textAbstract:
Abstract Background Among the 1.2 million people living with HIV (PLWH) in the U.S., many are covered by Medicare, a federally funded health insurance program for elderly (≥65 years) and disabled (< 65 years) individuals. Medicare has emerged as a major source of HIV care for PLWH. Given limited research in this population, a better understanding of patient characteristics, comorbidities, and comedication use among PLWH in the Medicare program is needed to help optimize clinical care. Methods A retrospective claims analysis of a national cross-sectional sample of fee-for-service (FFS) Medicare beneficiaries with continuous medical and prescription coverage in 2018 was conducted using 100% Medicare administrative claims. The PLWH group included individuals with ≥1 HIV diagnosis code in medical claims and ≥1 pharmacy claim for an anchor antiretroviral (ARV) drug (i.e., NNRTI, PI or InSTI) in 2018. The comparison group included a random sample of Medicare beneficiaries without HIV (PLWoH). Sociodemographic characteristics, comorbidities, and medication use were compared between PLWH and PLWoH. Results The study sample included 86,856 PLWH and 552,645 PLWoH. PLWH were more likely to be younger (mean age: 57.4 vs 71.1 years and < 65 years: 72% vs 18%), male (75% vs 42%), Black (42% vs 10%), eligible for Medicare due to disability (83% vs 27%) and receiving full low-income subsidies (77% vs 31%); all p< 0.001. Prevalence of >3 comorbidities was high in PLWH (70.2%) and only slightly lower than in PLWoH (71.7% p< 0.001). Prevalence of neuropsychiatric conditions, chronic kidney disease, liver disease, COPD, hepatitis B, and hepatitis C were higher in PLWH (Figure 1). The mean hierarchical condition categories risk score was higher in PLWH vs PLWoH (1.81 vs. 1.32; p< 0.001). On average, polypharmacy was higher among PLWH vs PLWoH (annual number of unique medications: 12.6 vs. 9.4 for all drugs and 10.3 vs. 9.4 for non-ARV drugs, both p< 0.001). Figure 1. Percentage of PLWH and PLWoH with multimorbidity and selected comorbid conditions. Abbreviations: COPD=chronic obstructive pulmonary disease; GI=gastrointestinal; PLWH=people living with HIV; PLWoH=people living without HIV All p-values <0.001 except GI Disorders (p=0.14). Conclusion In the Medicare FFS population, multimorbidity and polypharmacy were highly prevalent in PLWH despite their substantially younger age compared to PLWoH. Our findings highlight the need to consider comorbidities and comedications in HIV management including ARV regimens to minimize medication burden and drug interactions, which might improve clinical outcomes. Disclosures Pengxiang Li, PhD, Avalon Health Economics LLC (Consultant)COVIA Health Solutions (Consultant)Healthstatistics, LLC (Consultant) Jianbin Mao, PhD, Merck (Employee)Merck (Shareholder) Girish Prajapati, M.B.B.S., MPH , Merck & Co., Inc. (Employee, Shareholder) Robert Gross, MD, MSCE, Pfizer (Other Financial or Material Support, Serve on DSMB for drug unrelated to HIV) Jalpa A. Doshi, PhD, Acadia (Consultant, Advisor or Review Panel member)Allergan (Advisor or Review Panel member)Biogen (Grant/Research Support)Boehringer Ingelheim (Other Financial or Material Support, Scientific lecture)Catabasis (Consultant)Humana (Grant/Research Support)Janssen, Inc. (Consultant, Grant/Research Support)MeiraGTX (Consultant)Merck (Grant/Research Support, Advisor or Review Panel member)Novartis (Grant/Research Support)Otsuka (Advisor or Review Panel member)Regeneron (Grant/Research Support)SAGE Therapeutics (Consultant)Sanofi (Grant/Research Support)Shire (Advisor or Review Panel member)The Medicines Company (Advisor or Review Panel member)
44
El-Zastrouw, Ngatawi. "Menuju Sosiologi Nusantara: Analisa Sosiologis Ajaran Ki Ageng Suryomentaram dan Amanat Galunggung." ISLAM NUSANTARA: Journal for Study of Islamic History and Culture 1, no. 1 (July 30, 2020): 89–144. http://dx.doi.org/10.47776/islamnusantara.v1i1.46.
Full textAbstract:
The discourse on indigenizing of social sciences has been popular among Indonesian scholars since 1970s. However, it has not shown any significant development, in spite of many writings of Nusantara scholars that can be bases of references to develop sociological theories of Nusantara, such as the manuscripts of Kawruh Jiwo Ki Ageng Suryomentaram and Amanat Galunggung. Making an effort to indigenize social sciences of Nusantara, the present study investigates both manuscripts. The results of the study argue that there are basic theories of sociology discussed in those two manuscripts. For example, the concepts of social integration (kabuyutan), division of labor, and historical consciousness, which are discussed in the manuscript of Amanat Galunggung. The sociological perspective of Amanat Galunggung is very similar to the structural-functional theory. While, the concepts found in Kawruh Jiwo Ki Ageng Suryomentaram, such as the concepts of four division of human being, feeling (rasa) and intention (karep), and reciprocal relations between human and society. Those theories are genuine and authentical; and if the theories are developed, they will result in a typical of Nusantara sociological theory.
Keywords: Indigeneus, Kramadangsa, Rasa, Kabuyutan, Tri Tangtu
REFERENCE
Alatas, S.F., (2010), Diskusus Alternatif Dalam Ilmu Sosial Asia, Tanggapan Terhadap Eurocentrisme, Bandung, Mizan,
Anthony Giddens (1997), Central Problem in Social Theoty, Berkeley & Los Angeles: University of Callifornia Press.
Ary, H. Gunawan (2000), Sosiologi: Suatu Analisis Sosiologi tentang Pelbagai Problem Pendidikan, Cet. I; Jakarta: Rinika Cipta.
Astrid S. Susanto (1979) Pengantar Sosiologi dan Perubahan Sosial, Bandung, Binacipta.
Allice S. Rossi (ed.), 1985, Sosiology and Antropoly in the People’s Republic of China, National Academy Press, Washington DC.;
Bacthiar Wardi (2010). Sosiologi Klasik Dari Comte hingga Parsons. Bandung: Remaja Rosdakarya.
Bento, Ted dan Ian Craib (2009). Filsafat Ilmu Sosial Pendasaran Filosofis Bagi Pemikiran Sosial. Yogyakarta: Ledalero.
Budiman, Arif (1991), Negara dan Pembangunan; Study tentang Indonesia dan Korea Selatan, Jakarta Yayasan Padi Kapas.
Chambliss, Rollin (1954), Social Thought, New York, Dryden Press;
Danasasmita, S. (1987). Sewaka Darma, Sanghyang Siksakandang Amanat Galunggung. Bandung: BP3 Kebudayaan Sunda Depdikbud;
Drapper, Hal, (1978) “Karl Marx’s Theory of Revolution The Politics of Social Classes,” Vol. II, Monthly Review Press,
Faruk.(2010), Pengantar Sosiologi Sastra, dari Strukturalisme Genetik sampai Post Strukturalisme.Yogyakarta: Pustaka Pelajar
Heri Santoso, (1997), Dimensi Epistemoligis Dalam Indegenisasi Ilmu-Ilmu Sosial di Indonesia, Jurnal Edisi Khusus; hal. 188 dikutip dari https://media.neliti.com/media/ publications/228423-dimensi-epistemologis-dalam-indeginisasi-022d80a4.pdf, diakses pada 5 Agustus 2020.
Jacson, Karl D. and Lucian Pye (ed.), Political Power and Communication in Indonesia, Berkeley and Los Angles, University of California Press.
Jatman, Darmanto, (2000). Psikologi Jawa, Yogyakarta, Bentang Budaya;
----------------------, (2008), Ilmu Jiawa Kaum Pribumi (Indigeneus Psycology, Pidato Pengukuhan Guru Besar Psikologi Undip
Johnson, Doyle Paul (1986), Teori Sosiologi Klasik dan Modern, jilid 1 dan 2 (terj. Robert M.Z. Lawang), Jakarta, Gramedia
Noorduyn dan A. Teew, Tiga Pesona Sunda Kuno, terj. Hawe Setiawan, Jakarta: Pustaka Jaya,
Jones, (2003) Pengantar Teori-Teori Social: Dari Teori Fungsionalisme Hingga Post-Modernisme, (trj.Saifuddin), Jakarta: Pustaka Obor
Ki Fudyartanto, (2002), Psikologi Kepribadian Timur, Yogyakarta: Pustaka Pelajar;
Kuntowijoyo, (1990) Paradigma Islam; Interpretasi Untuk Aksi, Bandung, Mizan;
---------------, , (2001), Muslim tanpa Msjid, Bandung, Mizan;
Lubis, N. H. (2013). Sejarah Kerajaan Sunda.Bandung: Yayasan MSI;
Mas’ud, Mochtar (1994), Politik Birokrasi dan Pembangunan, Yogyakarta, Pustaka Pelajar
Mills, C. Wright and Hans Gerth, (1956), From Max Weber; Essays in Sociology, New York, Oxford University Press;
Nasiwan dan Yuyun Sri Wahyuni (2016), Seri Teoti-Teori Sosial Indonesia, Yogyakarta, UNY Press,
Prihartanti, (2004) Kepribadian sehat menurut konsep Suryomentaram, Surakarta: Muhammadiyah University Press;
Rangga Saptya Mohamad Permana, Makna Tri Tangtu di Buana Yang Mengandung Aspek Komunikasi Politik Dalam Framen Carita Prahyangan, Jurnal Kajian Komunikasi, Volume 3, No. 2, Desember 2015
Ratih Suryowiyono (2007), Ki Ageng Suryomentaram Sang Plato dari Jawa, Yogyakarta: Cemerlang Publishing,
Schutz, Alfred dan Thomas Luchmann, (1973), the Structure of the Life-World, Evanston, III; Northwetern University Press,
Soerjono Soekanto, (1985), Sosiologi Suatu Pengantar , Cet. V; Jakarta: CV Rajawali,
Sri Teddy Rusdi (2014), Epistemologi Ki Ageng Suryomentaram, Tandhesan Kawruh Bab Kawruh Jakarta: Yayasan Kertagama;
Suaedy, Ahmad (2018), Gusdur, Islam Nusantara dan Kewarganegaraan Bineka, Jakarta, Gramedia Pustaka Utama;
Sugiarto, Ryan, (2015), Psikologi Raos; Saintifikasi Kawruh Jiwo Ki Ageng Suryomentaram, Yogyakarta, Pustaka Ifada
Sumaryono, E. (1999). Hermeneutik: sebuah metode filsafat. Yogyakarta: Kanisisus
Suryomentaram, Grangsang (1990), Kawruh Jiwa, jilid 1-4, Jakarta: CV. Haji Masagung,
Suryalaga, H.R. Hidayat, (2010), Rawayan Jati Kasundaan, (Bandung, Yayasan Nurhdayah,
Turner, Jonathan H. (1990), The Strucrure of Sosiological Theory, Belimont, California, Wadsworth Publishing Company
Weber, Max (1947), The Theoty of Social and Economic Organzation, New York, Free Press and McMillan Publishing Company.
Sumber Internet
https://id.usembassy.gov/id/education-culture-id/program-fulbright-id/, diakses tanggal 17 Agustus 2020
https://id.usembassy.gov/id/amerika-serikat-berikan-satu-juta-dolar-dana-penelitian-untuk-enam-ilmuwan-indonesia/, diakses pada 5 Agustus 2020
https://id.usembassy.gov/id/amerika-serikat-dan-indonesia-resmikan-lima-pusat-kerjasama-penelitian-berkualitas-tinggi-di-indonesia/, diakses pada 5 Agustus 2020
45
Montero Fenollós, Juan-Luis. "De Mari a Babilonia: ciudades fortificadas en la antigua Mesopotamia." Vínculos de Historia Revista del Departamento de Historia de la Universidad de Castilla-La Mancha, no. 11 (June 22, 2022): 15–32. http://dx.doi.org/10.18239/vdh_2022.11.01.
Full textAbstract:
Las ciudades mesopotámicas estaban amuralladas desde sus orígenes. Muralla y ciudad, símbolo de civilización, eran dos conceptos inseparables. Por mandato de los dioses, el rey era el responsable de la fundación de las ciudades y de la construcción de sus sistemas de defensa, que fueron evolucionando como respuesta a los cambios producidos en el arte de la guerra en el Próximo Oriente antiguo. En este artículo se analiza, en particular, la documentación arqueológica y textual de dos modelos de ciudad fortificada: Mari (III-II milenio a. C.), en el norte, y Babilonia (II-I milenio a. C.), en el sur. Se realiza una nueva propuesta de interpretación del recinto defensivo interior de Babilonia. Palabras clave: Ciudades mesopotámicas, fortificacionesTopónimos: Habuba Kabira, Mari, BabiloniaPeríodo: IV-I milenio a. C. ABSTRACTMesopotamian cities were walled from their origins. Wall and city, a symbol of civilisation, were two inseparable concepts. By mandate of the gods, the king was responsible for the foundation of the cities and the construction of their defence systems, which evolved in response to changes in the art of warfare in the ancient Near East. This article analyses, in particular, the archaeological and textual documentation of two models of fortified cities: Mari (3rd-2nd millennium B.C.), in the north, and Babylon (2nd-1st millennium B.C.), in the south. A new approach to the interpretation of the inner wall of Babylon is proposed. Keywords: Mesopotamian cities, fortificationsPlace names: Habuba Kabira, Mari, BabylonPeriod: IVth-Ist millennium B. C. REFERENCIASAbrahami, Ph. (1997), L’armée à Mari, tesis doctoral, Université de Paris I (inédita).al-Rawi, F.N.H. (1985), “Nabopolassar’s Restoration Work on the Wall Imgur-Enlil at Babylon”, Iraq, 47, pp. 1-9.Aurenche, O. (dir.) (1977), Dictionnaire illustré multilingue de l’architecture du Proche Orient Ancien, Lyon, MOM.Azara, P. (dir.) (2000), La fundación de la ciudad. Mesopotamia, Grecia y Roma, Barcelona, CCCB.Battini, L. (1996), “Un exemple de propagande néoassyrienne: les défenses de Dur-Sharrukin”, CMAO, 6, pp. 215-234.— (1997), “Les sytèmes défensifs à Babylone”, Akkadica, 104-105, pp. 24-55.Becker, H., van Ess, M., Fassbinder, J. (2019), “Uruk: Urban Structures in Magnetic and Satellite Images”, en Uruk. First City of the Ancient World, Los Angeles, Getty Museum.Burke, A. A. (2008), “Walled up to Heaven”. The Evolution of Middle Bronze Age Fortifications Strategies in the Levant, Winona Lake, Eisenbrauns.Butterlin, P. (2016), “Villes de Mésopotamie, D’Uruk à Babylone”, en L’histoire commence en Mésopotamie, París, Louvre, pp. 166-171.— (2020), “Mari, une ville circulaire ordinaire?”, en Circular Cities of Early Bronze Age Syria, Turnhout, Breplos, pp. 265-273.Chavalas, M. (ed.) (2006), Historical Sources in Translation. The Ancient Near East, Malden, Blackwell.Childe, V. G. (1992), Los orígenes de la civilización, México DF, FCE (1ª edición de 1936).Collon, D. (2008), “Le développement de l’arc en Mésopotamie”, en Les armées du Proche-Orient ancien (IIIe et Ier mil. av. J.-C.), Oxford, BAR.Durand, J. M. (1997), Les documents épistolaires du palais de Mari, tome I, Paris, Éditions du Cerf.— (1998), Les documents épistolaires du palais de Mari, tome II, Paris, Éditions du Cerf.George, A. R. (1992), Babylonian Topographical Texts, Leuven, Peeters.Herzog, Z. (1997), “Fortifications”, en The Oxford Encyclopedia of Archaeology in the Near East, New York-Oxford, Oxford University Press, pp. 319-326.Hnaihen, K. H. (2020), The Defensive Brick Architecture in Mesopotamia from the end of Early Bronze Age to th end of Early Iron Age, tesis doctoral, Universidad de Almería (inédita).Houben, H. y Guillaud, H. (2006), Traité de construction en terre, Marseille, Éditions Parenthèses.Kenyon, K. M. (1963), Arqueología en Tierra Santa, Barcelona, Ediciones Garriga.Lackenbacher, S. (2001), “Fondations assyriennes”, en Mites de fundació de ciutats al món antic (Mesopotàmia, Grècia i Roma), Barcelona, MAC, pp. 69-74.Liverani, M. (2006), Uruk. La primera ciudad, Barcelona, Edicions Bellaterra.— (2014), Imaginar Babel. Dos siglos de estudios sobre la ciudad oriental antigua, Barcelona, Edicions Bellaterra.Ludwig (1980), “Mass, Sitte und Technik des Bauens in Habuba-Kabira Süd”, en Le Moyen Euphrate, zone de contactes et d’échanges, Leyden, Brill, pp. 63-74.Margueron, J. C. (2000), “Nacimiento y fundación de ciudades en Mesopotamia”, en La fundación de la ciudad. Mesopotamia, Grecia y Roma, Barcelona, CCCB, pp. 33-48.— (2004), Mari. Métropole de l’Euphrate au IIIe et au Début du IIe millénaire av. J.-C., Paris, Picard-ERC.— (2009), “La fondation de Mari. Première aproche d’une technologie de fondation”, Estudos Orientais, 10, pp. 13-33.— (2011), “Aux origines de l’architecture militaire en Mésopotamie”, en Stratégies de défense, de conquête ou de victoire en Méditerranée des textes aux architectures et à l’aménagement, Tlemcen, pp. 11-45.— (2012), “Du village à la ville: continuité ou rupture?”, en Du village néolithique à la ville syro-mésopotamienne, Ferrol, PAMES-UDC, pp. 67-97.— (2013), Cités invisibles. La naissance de l’urbanisme au Proche-Orient ancien, París, Paul Geuthner— (2014), Mari. Capital of Northern Mesopotamia in the Third Millennium, Oxford-Philadelphia, Oxbow Books.Mazar, A. (1995), “The Fortification of Cities in the Ancient Near East”, en Civilizations of the Ancient Near East, volumes III-IV, Peabody, Hendrickson Publishers, pp. 1523-1537.Mielke, D. P. (2012), “Fortifications and Fortification Strategies of Mega-Cities in the Ancient Near East”, en Mega-cities Mega-sites, the Archaeology of Consumption Disposal, Landscape, Transport Communication, 7th ICAANE vol. 1, Wiesbaden, Harrassowitz Verlag, pp. 74-91.Montero Fenollós, J. L. (2004), “Revisando a Gordon Childe, el concepto de Revolución Metalúrgica en los albores de la historia de Mesopotamia”, en Miscelánea en homenaje a Emiliano Aguirre, Alcalá de Henares, Museo Arqueológico Regional, pp. 312-319.— (2017), “Bronze Metallurgy in the Times of Earliest Cities. New Data on the City I of Mari”, Ash-Sharq, 1, pp. 48-54.— (2019), “La frontera noroccidental del reino de Mari a comienzos del II milenio a. C. a la luz de los textos y la arqueología. Reflexiones sobre la localización de Dur-Yahdun-Lim”, Claroscuro, 18, pp. 1-21.Nadali, D. (2007), “Ashurbanipal against Elam. Figurative Patterns and Architectural Location of Elamite Wars”, Historiae, 4, pp. 57-91Nigro, L. (2015), “Tell es-Sultan 2015. A Pilot Project for Archaeology in Palestine”, Near Eastern Archaeology, 79, pp. 4-17.Pedersén, O. (2011), “Excavated and Unexcavated Libraries un Babylon”, en Babylon. Wissenskultur in Orient und Okzident, Berlin-Boston, De Gruyter, pp. 47-67.— (2021), Babylon. The Great City, Münster, Zaphon.Reade J. E. (2008), “Early Travellers on the Wonders: Suggested Sites”, en Babylon: Myth and Reality, London, British Museum, pp, 112-118.Rey, S. (2012), Poliorcétique au Proche-Orient à l’âge du Bronze. Fortifications urbaines, procédés de siège et systèmes défensifs, Beyrouth, IFPO.Sanmartín, J. (2018), Gilgamesh, rey de Uruk, Madrid, Trotta.Sasson, J.M. (1969), The Military Establishments at Mari, Roma, Pontifical Biblical Institute.Sollberger, E., Kupper, J. R. (1971), Inscriptions royales sumériennes et akkadiennes, Paris, Éditions du Cerf.Thomas, A. (dir.) (2016), L’histoire commence en Mésopotamie, París, Louvre.Van Ess, M. (2008), “Koldewey, Pionier systematicher Ausgrabungen im Orient”, en Auf dem weg nach Babylon. Robert Koldewey. Ein Archäologenleben, Mainz, Verlag Philipp von Zabern, pp. 91-103.Vidal, J. (2012), “La guerra de asedio en el período paleobabilónico según los textos de Mari”, en Fortificaciones y guerra de asedio en el mundo antiguo, Zaragoza, Libros Pórtico, pp. 21-35.Wetzel, F. (1969), Stadtmauer von Babylon, Osnabrück, Otto Zellen.Yadin, Y. (1963), The Art of Warfare in Biblical Lands, 2 vols., New York-Toronto-Londres, McGraw-Hill Book Company.
46
Mack, Andrew R., Christopher Bethel, Steven Marshall, Robin Patel, Robin Patel, David van Duin, Vance G. Fowler, et al. "1063. ARGONAUT-V: Susceptibility of Multidrug-Resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S623—S624. http://dx.doi.org/10.1093/ofid/ofab466.1257.
Full textAbstract:
Abstract Background P. aeruginosa is a Gram-negative pathogen responsible for many serious infections. MDR, both intrinsic and acquired, presents major clinical challenges. Taniborbactam (formerly VNRX-5133; Fig 1) is a β-lactamase inhibitor (BLI) characterized as a bicyclic boronate, uniquely possessing activity toward all four Ambler classes of β-lactamases, both serine and metallo, with the exception of class B IMP β-lactamases. The β-lactam-BLI (BL-BLI) combination cefepime-taniborbactam (FTB; Fig 1) is currently in phase 3 clinical trials. Structures of taniborbactam and cefepime. The β-lactamase inhibitor is in red and the β-lactam antibiotic is in black. Methods The activity of FTB was tested against 197 well-characterized clinical P. aeruginosa isolates that were part of PRIMERS (Platforms for Rapid Identification of MDR-Gram-negative bacteria and Evaluation of Resistance Studies). Nearly 58% of these strains were reported as carbapenem-non-susceptible. Porin changes, efflux pumps, and/or the presence of acquired class A or class B carbapenemases were previously reported. Broth microdilution minimum inhibitory concentrations (MICs) were determined by CLSI M07 Ed. 11 methods with custom Sensititre frozen panels and interpreted using CLSI M100 Ed. 30 breakpoints. American Type Culture Collection strains were used for quality control. FEP breakpoints were provisionally used for FTB, where taniborbactam was fixed at 4 µg/mL. Results Percent susceptibility to BL agents alone was 45.2% for imipenem (IPM), 55.8% for meropenem (MEM), 60.9% for ceftazidime (CAZ), and 67.0% for FEP. The addition of BLI to BL increased % susceptibility for MEM-vaborbactam (MVB), 56.9%; ceftolozane-tazobactam (C/T), 77.7%, CAZ-avibactam (CZA), 79.7%, and FTB, 82.7%. MIC50s were in the susceptible range for all drugs except IPM, which was intermediate, and all MIC90s were in the resistant range (Table 1). Taniborbactam reduced FEP MIC by 2-fold in 32% of isolates and ≥ 4-fold in 13% of isolates. Against carbapenem-non-susceptible strains, % susceptibilities were: FTB, 68.5%, CZA, 63.0%, C/T, 59.3%; and MVB, 21.3% (Table 2). MIC50 and MIC90 values (µg/mL) and percent susceptibility (%S) for all P. aeruginosa strains (n=197). AMK, amikacin; ATM, aztreonam; C/T, ceftolozane-tazobactam; CAZ, ceftazidime; CZA, ceftazidime-avibactam; FEP, cefepime; FTB, cefepime-taniborbactam; IPM, imipenem; MEM, meropenem; MVB, meropenem-vaborbactam; TZP, piperacillin-tazobactam; TOB, tobramycin. *The breakpoints for FEP and MEM alone were provisionally applied to FTB and MVB, respectively. Tazobactam, avibactam, and taniborbactam were fixed at 4 µg/mL, while vaborbactam was fixed at 8 µg/mL. Breakpoints from CLSI M100, 31st ed, 2021. MIC50 and MIC90 values (µg/mL) and percent susceptibility (%S) for the subset of carbapenem-non-susceptible P. aeruginosa strains (n=108). AMK, amikacin; ATM, aztreonam; C/T, ceftolozane-tazobactam; CAZ, ceftazidime; CZA, ceftazidime-avibactam; FEP, cefepime; FTB, cefepime-taniborbactam; IPM, imipenem; MEM, meropenem; MVB, meropenem-vaborbactam; TZP, piperacillin-tazobactam; TOB, tobramycin. *The breakpoints for FEP and MEM alone were provisionally applied to FTB and MVB, respectively. Tazobactam, avibactam, and taniborbactam were fixed at 4 µg/mL, while vaborbactam was fixed at 8 µg/mL. Breakpoints from CLSI M100, 31st ed, 2021. Conclusion Compared to MVB, CZA, and C/T, FTB demonstrated the greatest activity against the 197 P. aeruginosa strains tested, including many carbapenem-non-susceptible strains. Pending completion of clinical development, FTB may be a promising therapeutic option for MDR P. aeruginosa infections. Disclosures Robin Patel, MD, 1928 Diagnostics (Consultant)BioFire Diagnostics (Grant/Research Support)ContraFect Corporation (Grant/Research Support)Curetis (Consultant)Hylomorph AG (Grant/Research Support)IDSA (Other Financial or Material Support, Editor’s Stipend)Infectious Diseases Board Review Course (Other Financial or Material Support, Honoraria)Mammoth Biosciences (Consultant)NBME (Other Financial or Material Support, Honoraria)Netflix (Consultant)Next Gen Diagnostics (Consultant)PathoQuest (Consultant)PhAST (Consultant)Qvella (Consultant)Samsung (Other Financial or Material Support, Patent Royalties)Selux Diagnostics (Consultant)Shionogi & Co., Ltd. (Grant/Research Support)Specific Technologies (Consultant)TenNor Therapeutics Limited (Grant/Research Support)Torus Biosystems (Consultant)Up-to-Date (Other Financial or Material Support, Honoraria) Robin Patel, MD, BioFire (Individual(s) Involved: Self): Grant/Research Support; Contrafect (Individual(s) Involved: Self): Grant/Research Support; IDSA (Individual(s) Involved: Self): Editor’s stipend; NBME, Up-to-Date and the Infectious Diseases Board Review Course (Individual(s) Involved: Self): Honoraria; Netflix (Individual(s) Involved: Self): Consultant; TenNor Therapeutics Limited (Individual(s) Involved: Self): Grant/Research Support; to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, Torus Biosystems, Mammoth Biosciences and Qvella (Individual(s) Involved: Self): Consultant David van Duin, MD, PhD, Entasis (Advisor or Review Panel member)genentech (Advisor or Review Panel member)Karius (Advisor or Review Panel member)Merck (Grant/Research Support, Advisor or Review Panel member)Pfizer (Consultant, Advisor or Review Panel member)Qpex (Advisor or Review Panel member)Shionogi (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member)Utility (Advisor or Review Panel member) Vance G. Fowler, Jr., MD, MHS, Achaogen (Consultant)Advanced Liquid Logics (Grant/Research Support)Affinergy (Consultant, Grant/Research Support)Affinium (Consultant)Akagera (Consultant)Allergan (Grant/Research Support)Amphliphi Biosciences (Consultant)Aridis (Consultant)Armata (Consultant)Basilea (Consultant, Grant/Research Support)Bayer (Consultant)C3J (Consultant)Cerexa (Consultant, Other Financial or Material Support, Educational fees)Contrafect (Consultant, Grant/Research Support)Debiopharm (Consultant, Other Financial or Material Support, Educational fees)Destiny (Consultant)Durata (Consultant, Other Financial or Material Support, educational fees)Genentech (Consultant, Grant/Research Support)Green Cross (Other Financial or Material Support, Educational fees)Integrated Biotherapeutics (Consultant)Janssen (Consultant, Grant/Research Support)Karius (Grant/Research Support)Locus (Grant/Research Support)Medical Biosurfaces (Grant/Research Support)Medicines Co. (Consultant)MedImmune (Consultant, Grant/Research Support)Merck (Grant/Research Support)NIH (Grant/Research Support)Novadigm (Consultant)Novartis (Consultant, Grant/Research Support)Pfizer (Grant/Research Support)Regeneron (Consultant, Grant/Research Support)sepsis diagnostics (Other Financial or Material Support, Pending patent for host gene expression signature diagnostic for sepsis.)Tetraphase (Consultant)Theravance (Consultant, Grant/Research Support, Other Financial or Material Support, Educational fees)Trius (Consultant)UpToDate (Other Financial or Material Support, Royalties)Valanbio (Consultant, Other Financial or Material Support, Stock options)xBiotech (Consultant) Daniel D. Rhoads, MD, Becton, Dickinson and Company (Grant/Research Support) Michael Jacobs, MBBS, Venatorx Pharmaceuticals, Inc. (Grant/Research Support) Focco van den Akker, PhD, Venatorx Pharmaceuticals, Inc. (Grant/Research Support) David A. Six, PhD, Venatorx Pharmaceuticals, Inc. (Employee) Greg Moeck, PhD, Venatorx Pharmaceuticals, Inc. (Employee) Krisztina M. Papp-Wallace, Ph.D., Merck & Co., Inc. (Grant/Research Support)Spero Therapeutics, Inc. (Grant/Research Support)Venatorx Pharmaceuticals, Inc. (Grant/Research Support)Wockhardt Ltd. (Other Financial or Material Support, Research Collaborator) Robert A. Bonomo, MD, entasis (Research Grant or Support)Merck (Grant/Research Support)NIH (Grant/Research Support)VA Merit Award (Grant/Research Support)VenatoRx (Grant/Research Support)
47
Grégoire, Jean-Marie. "Antiarrhythmic Therapy, Gunter Breithardt, A. John Camm, Ronald W. F. Campbell, Harry A. Fozzard, Brian F. Hoffman, Michiel J. Janse, Ralph Lazzara, Samuel Levy, Robert J. Myerburg, Dan M. Roden, Michael R. Rosen, Peter J. Schwaartz, Harold C. Strauss, Albert L. Waldo, Andrew L. Wit, Raymond L. Woosley, Antonio Zaza, Douglas P. Zipes, for the Sicilian Gambit, Futura Publishing Company, Inc., Armonk, N.Y. (1994) 194 pages, illustrated, $65.00 ISBN: 0-87993-596-0." Clinical Cardiology 18, no. 10 (October 1995): 601. http://dx.doi.org/10.1002/clc.4960181016.
Full text
48
Jayatilleke, C. N. R., A. Anilkumar, S. Janagan, R. W. Marshall, S. Skeoch, C. Guly, F. E. Sin, et al. "AB0589 TOCILIZUMAB FOR GIANT CELL ARTERITIS: BASELINE AND TWELVE MONTH AUDIT DATA FROM THE UK BRISTOL AND BATH MULTIDISCIPLINARY MEETING." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1420.2–1421. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2872.
Full textAbstract:
BackgroundGiant Cell Arteritis (GCA) is a systemic vasculitis involving large and medium-sized blood vessels. Treatment is with high dose glucocorticoids. Steroid-sparing agents and Tocilizumab (TCZ) are used for refractory or relapsing cases. NHS England requires all GCA patients to be discussed in a regional multidisciplinary team meeting (MDT) prior to commencing TCZ. TCZ has only been permitted for a maximum of one year; this time limitation was extended during the Covid-19 pandemic (1). The monthly virtual Bristol and Bath regional MDT started in November 2018.ObjectivesWe aimed to review: 1) Baseline data on all patients referred to the Bristol and Bath TCZ for GCA MDT, including demographics, clinical presentation and previous steroid-sparing agents used and 2) 12 month follow up data including number of completions, adverse effects, and flares on treatment.MethodsThe TCZ MDT referral proforma, adapted from the NHS England Blueteq approval form, was reviewed for all patients referred. 12 month follow up data was obtained from clinic letters.ResultsBaseline dataThirty-eight cases were referred between November 2018 and September 2021. Of these, 31 were approved for TCZ usage; 100% fulfilled the criteria for either refractory (n=11) or relapsing (n=20) disease. Mean age was 74 years and 74.2% were female. Average disease duration was 161.5 days for the refractory and 827.3 days for the relapsing group.77.4% had cranial GCA, 48.4% had large vessel involvement, 45.2% had visual symptoms and 25.8% had ischaemic visual loss. The positive investigations were PET-CT (48.4%), temporal artery ultrasound (41.9%) and temporal artery biopsy (32.3%).64.5% had trialled a steroid-sparing agent at time of referral (61.3 % methotrexate, 9.7% azathioprine, 6.5% leflunomide), 35.5% had received intravenous methylprednisolone and 58% were receiving greater than 40mg prednisolone at the time of referral.Glucocorticoid adverse effects of osteoporosis, weight gain, cataracts and hypertension were each seen in 19.4%; whilst diabetes, neuropsychiatric symptoms and sleep disturbance were each reported in 16.1%.Those with ocular involvement tended to be referred earlier than those without (478.2 days vs 648.1 days), were referred on higher doses of glucocorticoids (71.4% vs 47.1% on ≥ 40mg) and had less steroid-sparing agents prior to referral.Follow up dataIn December 2021, a follow-up audit revealed 14/31 patients had completed at least 12 months of tocilizumab; 5 of these had had an extension under Covid-19 exceptional guidance (mean duration of 5.2 months). Of the remaining 17: 3 patients had stopped early (1 death, 1 moved away, 1 due to adverse effects of headache and gastro-intestinal side effects), 4 had not started tocilizumab and 10 had not completed 12 months of treatment at that point.Adverse events in the 14 patients at 12 months included: liver abnormalities (2/14; 14.3%), neutropenia (2/14; 14.3%), thrombocytopaenia (1/14; 7.1%), soft tissue infections (3/14; 21.4%), urinary tract infection (1/14; 7.1%) and lipid derangement (4/14 28.6%). One case of GCA relapse occurred on TCZ (mild headache and raised inflammatory markers settled on small increase in prednisolone). After 12 months, mean prednisolone dose was 3mg (range 0-15mg).ConclusionAll patients approved for Tocilizumab in the GCA MDT fulfilled NHS England criteria for either relapsing or refractory disease. The majority of cases had cranial disease, but almost half had either ocular or large vessel involvement, reflecting a severe spectrum of disease. Cases showed a high burden of glucocorticoid toxicity. Follow up data suggests that TCZ was effective in allowing glucocorticoid weaning and disease control, but with some adverse effects. Future work to follow up patients after stopping Tocilizumab would be informative, as the twelve month limitation on treatment is likely to be re-instated.References[1]https://www.england.nhs.uk/coronavirus/publication/tocilizumab-for-giant-cell-arteritis-gca-during-the-covid-19-pandemic-rps-2007/Disclosure of InterestsChandrin N. R. Jayatilleke: None declared, Aishwarya Anilkumar: None declared, Shalini Janagan: None declared, Robert W Marshall: None declared, Sarah Skeoch: None declared, Catherine Guly Grant/research support from: Eli Lilly and Company - paid consultant for a research trial, Fang En Sin: None declared, Keziah Austin: None declared, Laith Al-Sweedan: None declared, Alexandra Bourn: None declared, Lynsey Clarke: None declared, Harsha Gunawardena: None declared, Baashar Boyce: None declared, Sally Knights: None declared, John D Pauling: None declared, Elizabeth Reilly: None declared, Timothy D Reynolds: None declared, Sarah Villar: None declared, Joanna C Robson: None declared
49
Nuryani, Nunung. "PENGARUH BIAYA AUDIT TERHADAP KUALITAS AUDIT DAN DETERMINAN BIAYA AUDIT." Jurnal Akuntansi 9, no. 2 (August 15, 2020): 32–47. http://dx.doi.org/10.46806/ja.v9i2.760.
Full textAbstract:
Financial information is one of the important information in decision making. However, many cases of fraud committed by management so that the information in the financial statements cannot be relied upon in decision making. Therefore, the auditor's job is to ensure that the company's financial statements are represented correctly (faithful representation) so that financial statement information becomes more quality and useful in making decisions. So this study aims to examine the effect of audit fee on audit quality. In addition, this study also examines important determinants of audit costs, namely company size, profitability, audit risk, complexity, and firm size. By using the purposive sampling method, samples of the financial and manufacturing industry in 2010-2017 used are 39 firms per year. This sample is used to examine the effect of audit fee on audit quality and the determinant of audit fee using simple linear regression analysis and multiple linear regression analysis. The result of this research shows that audit fees have a significant positive effect on audit quality. In addition, this study shows that firm size, complexity, and firm size are important determinants that determine audit fee. However, profitability and audit risk have not been proven to explain audit fees.
Keywords: Audit Quality, Audit Fee, Firm Size, Profitability, Audit Risk, Complexity, Auditor Size
Referencens:
Al-Harshani, Meshari O. (2008), The pricing of audit services: Evidence from Kuwait. Managerial Auditing Journal, 23(7), 685–696.
Al-Thuneibat, Ali. Abedalqader, Ream Tawfiq Ibrahim Al Issa, & Rana Ahmad Ata Baker, (2011), Do audit tenure and firm size contribute to audit quality? Empirical evidence from Jordan. Managerial Auditing Journal, 26(4), 317–334.
Arens, Alvin A., Randal J. Elder,. Mark S. Beasley (2014), Auditing and Assurance Services: An Integrated Approach. United States: Pearson Education, Inc.
Association of Certified Fraud Examiners (2018), Report to the Nations: 2018 Global Study on Occupational Fraud and Abuse, United States: ACFE.
Bhandari, L. C. (1988), Debt/Equity Ratio and Expected Common Stock Returns : Empirical Evidence. The Journal of Finance, 43(2), 507–528.
Bowerman, Bruce L., Richard T. O'Connell, Emily S. Murphree (2017), Business Statistics in Practice, Eighth Edition, New York: McGraw Hill Education.
Brealey, Richard A., Myers, Stewart C. (2000), Principles of Corporate Finance, Boston: McGraw Hill Companies, Inc.
Carey, P. J. (2008), The Benefits of Services Provided by External Accountants to Small and Medium Sized Enterprises.
Carey, P., & Simnett, R. (2006), Audit partner tenure and audit quality. Accounting Review, 81(3), 653–676.
Castro, Walther Bottaro de Lima, Ivam Ricardo Peleias, & Glauco Peres da Silva (2015), Determinants of Audit Fees: A Study in the Companies Listed on the BM&FBOVESPA, Brasil. Revista Contabilidade & Finanças, 26(69), 261–273.
Chen, C. (2008), Audit Partner Tenure , Audit Firm Tenure , and Discretionary Accruals : Does Long Auditor Tenure Impair Earnings Quality ?, 25(2), 415–445.
Cooper, D. R., & Schindler, P. S. (2014), Business Research Methods (Twelfth Edition). New York: McGraw-Hill/Irwin.
DeAngelo, L. E. (1981), Auditor size and audit quality. Journal of Accounting and Economics, 3(3), 183–199.
Dechow, Patricia. M., Richard. G. Sloan, & Amy P. Sweeney (1995), Detecting Earnings Management. The Accounting Review.
DeFond, M., & Zhang, J. (2014), A review of archival auditing research. Journal of Accounting and Economics, 58(2–3), 275–326.
Deis, Donald R., & Gary Giroux (1996), The effect of auditor changes on audit fees, audit hours, and audit quality. Journal of Accounting and Public Policy, 15(1), 55–76.
Eilifsen, Aasmund, Jr William F Messier, Steven M Glover, Douglas F Prawitt (2014), Auditing & Assurance Services, Third Edition, London: McGraw-Hill.
Ettredge, Michael., Elizabeth Emeigh Fuerherm, & Chan Li (2014), Fee pressure and audit quality. Accounting, Organizations and Society, 39(4), 247–263.
Ferri, Michael G., & Wesley H. Jones (1979), Determinants of financial structure: a new methodological approach. The Journal of Finance, 34(3), 631–643.
Francis, Jere. R. (2011), A Framework For Understanding And Researching Audit Quality. Auditing, 30(2), 125–152.
Ghozali, H. Imam (2016), Aplikasi Analisis Multivariete dengan Program IBM SPSS 23, Edisi ke-8, Semarang: Badan Penerbit Universitas Diponegoro.
Gitman, Lawrence J., Chad J. Zutter (2012), Principles Of Managerial Finance (Thirteenth). United States: Lawrence J. Gitman.
Hoitash, Rani., Ariel Markelevich, & Charles A. Barragato (2007), Auditor fees and audit quality. Managerial Auditing Journal, 22(8), 761–786.
Horngren, Charles T., L. Sundem, John A. Elliott (1999), Introduction to Financial Accounting, Seventh Edition, New Jersey: Prentice-Hall,Inc.
Ikatan Akuntansi Indonesia (2017), Standar Akuntansi Keuangan (SAK), Jakarta: IAI
International Accounting Standard Board (2018), The Conceptual Framework for Financial Reporting 2018. London : IASB.
Jan, Chyan Long (2018), An effective financial statements fraud detection model for the sustainable development of financial markets: Evidence from Taiwan. Sustainability (Switzerland), 10(2).
Jensen, Michael C., & William H. Meckling (1976), Theory Of The Firm : Managerial Behavior , Agency Costs And Ownership Structure, 3, 305–360.
Joshi, P. L., & Hasan AL-bastaki (2000), Determinants of Audit Fees : Evidence from the Companies Listed in Bahrain, 138(November 1999), 129–138.
Jubb. (1996), Audit fee determinants: The plural nature of risk. Managerial Auditing Journal, 11(3), 25–40.
Kieso, Donald E., Jerry J. Weygandt, & Paul D. Kimmel (2013), Financial Accounting IFRS Edition. United States: John Wiley & Sons, Inc.
Kieso, Donald E, Jerry J Weygandt, Terry D Warfield (2018), Intermediate Accounting: IFRS Edition Third Edition, United States: John Willey & Sons, Inc.
Kikhia, Hassan Yahia (2014), Determinants of Audit Fees: Evidence from Jordan. Accounting and Finance Research, 4(1), 42–53.
Knechel, Robert W., & Ann Vanstraelen (2007), The Relationship between Auditor Tenure and Audit Quality Implied by Going Concern Opinions. AUDITING: A Journal of Practice & Theory, 26(May), 113–131.
Knechel, W. Robert, Gopal V. Krishnan, Mikhail Pevzner, Lori B Shefchik, & Uma K. Velury (2013), Audit quality: Insights from the academic literature. Auditing, 32(SUPPL.1), 385–421.
Konrath, Larry F. (2002), Auditing A Risk Analysis Approach, Fifth Edition, South Western.
Kusharyanti (2013), Analysis of the Factors Determining the Audit Fee. Journal of Economics, Business, and Accountancy | Ventura, 16(1), 147–160.
Lennox, C. (1999), Are large auditors more accurate than small auditors? Accounting and Business Research, 29(3), 217–227.
Lennox, C. S. (1999) Audit quality and auditor size: An evaluation of reputation and deep pockets hypotheses. Journal of Business Finance and Accounting, 26(7–8), 789–805.
Liu, Siheng. (2017), An Empirical Study: Auditors’ Characteristics and Audit Fee. Open Journal of Accounting, 06(02), 52–70.
Lobo, Gerald, & Yuping Zhao (2013), Relation between Audit Effort and Financial Report Misstatements: Evidence from Quarterly and Annual Restatements. Journal of International Accounting Research, 90(4), 1395–1435.
Manry, David L, Theodore J. Mock, & Jerry L. Turner (2008), Does increased audit partner tenure reduce audit quality? Journal of Accounting, Auditing and Finance, 23(4), 553–572.
Mohammed, Nishtiman Hashim, & Abdullah Saeed Barwari (2018), Determinants of Audit Fees : Evidence from UK Alternative Investment Market. Academic Journal of Nawroz University, 7(3), 34–47.
Musah, A. (2017), Determinants of Audit fees in a Developing Economy: Evidence from Ghana. International Journal of Academic Research in Business and Social Sciences, 7(11).
Newton, Nathan J., Dechun Wang, & Michael S. Wilkins (2013), Does a lack of choice lead to lower quality? evidence from auditor competition and client restatements. Auditing, 32(3), 31–67.
Nikkinen, J., & Petri Sahlström (2004), Does Agency Theory Provide a General Framework for Audit Pricing ? International Journal of Auditing, 8, 253–262.
Ohidoa, T., & Okun, O. O. (2018), Firms Attributes and Audit Fees in Nigeria Quoted Firms. International Journal of Academic Research in Business and Social Sciences, 8(3), 685–699.
Pham, Ngoc Kim, Hung Nguyen Duong, Tin Pham Quang, & Nga Ho Thi Thuy (2017), Audit Firm Size, Audit Fee, Audit Reputation and Audit Quality: The Case of Listed Companies in Vietnam. Asian Journal of Finance & Accounting, 9(1), 429.
Rahman, Dr Onaolapo Adekunle Abdul, Ajulo Olajide Benjamin, Onifade Hakeem Olayinka (2017), Effect of Audit Fees on Audit Quality: Evidence from Cement Manufacturing Companies in Nigeria. Effect of Audit Fees on Audit Quality: Evidence from Cement Manufacturing Companies in Nigeria., 5(1), 6–17.
Rahmina, Listya Yuniastuti, & Sukrisno Agoes (2015), Influence of Auditor Independence, Audit Tenure, and Audit Fee on Audit Quality of Members of Capital Market Accountant Forum in Indonesia. Procedia - Social and Behavioral Sciences, 164(August), 324–331.
Republik Indonesia (2008), Undang-Undang Republik Indonesia Nomor 20 tahun 2008 Tentang Usaha Mikro, Kecil, Dan Menengah.
Sandra, & Patrick. (1996), The Deteminants of Audit Fees in HongKong: An Empirical Study. Asian Review of Accounting, 4(2), 32–50.
Scott, William R (2015), Financial Accounting Theory, Seventh Edition, United States: Pearson Canada Inc.
Shibano, T. (1990), Assessing Audit Risk from Errors and Irregularities. Journal of Accounting Research, 28(1990), 110.
Sivathaasan, N., R. Tharanika, M. Sinthuja, V. Hanitha (2013), Factors determining Profitability: A Study of Selected Manufacturing Companies listed on Colombo Stock Exchange in Sri Lanka. European Journal of Business and Management, 5(27), 99-107–107.
Subramanyam, K. R. (2014), Financial Statement Analysis, Eleventh Edition, New York: McGraw-Hill Education.
Sun, Jerry, & Guoping Liu (2011), Client-specific litigation risk and audit quality differentiation. Managerial Auditing Journal, 26(4), 300–316.
Tritschler, Jonas (2013), Audit Quality: Association Between Published Reporting Errors and Audit Firm Characteristics.
Vu, Dinh Ha Thu Vu (2012), Determinants of audit fees for Swedish listed non-financial firms in NASDAQ OMX Stockholm.
Whittington, Ray & Kurt Pany (2004), Principles of Auditing and Other Assurance Services, New York: McGraw-Hill/Irwin.
Williams, David D. (1988), The Potential Determinants of Auditor Change. Journal of Business Finance & Accounting, 15(2), 243–261.
Wooten, T. C. (2003), Research About Audit Quality.
Wu, Shu-Hsing, Tsung-Che Wu, & Kun-Lin Yang (2017), Fair Value Information, Audit fees and Audit Committee in Taiwan. International Journal of Financial Research, 8(2), 124.
Xu, Jiabing (2017), Analysis on the Relationship between Audit Fee Management and Audit Quality in China, 53(ICEM 2017), 530–533.
50
Gordon, Oren, Donald Lee, Brooke Langevin, Alvaro A. Ordonez, Dustin Dikeman, Babar Shafiq, John Thompson, et al. "125. Dynamic PET facilitated Pharmacokinetic Modeling and High-dose Rifampin Regimens for Staphylococcus aureus Orthopedic Implant Associated Infections: Bench to Bedside." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S75—S76. http://dx.doi.org/10.1093/ofid/ofab466.125.
Full textAbstract:
Abstract Background Rifampin, has potent, dose-dependent sterilizing activity against Gram-positive bacteria with the area under the concentration-time curve (AUC) being the most predictive of bactericidal activity. Combination therapy with rifampin (10-15 mg/kg/day) is recommended to treat S. aureus orthopedic implant associated infections. Recently, high-dose rifampin (35 mg/kg/day) has been shown to be safe in humans and is being evaluated to shorten tuberculosis treatments. Methods Dynamic 11C-rifampin (chemically identical to rifampin) positron emission tomography (PET) was used to determine rifampin bone exposures (AUC) in mice and patients with S. aureus bone infection (Figure 1). PET data facilitated a pharmacokinetic model to predict rifampin concentration-time profiles in bone tissues, which were used to design studies in a mouse model of S. aureus orthopedic implant infection utilizing advanced imaging. Figure 1. Experimental schematics. (A) A validated mouse model of S. aureus orthopedic implant associated infection was used to determine bone concentrations following administration of escalating rifampin oral dosing (human equipotent dosing is indicated). m/z, mass/charge ratio. (B) Human patients and mice with S. aureus orthopedic infection were imaged using 11C-rifampin PET / CT. PET signal was quantified in infected and uninfected bone to generate time-activity curves (TACs) used to calculate area under the concentration time curve (AUC) over 45-90 minutes. These data were used to develop a pharmacokinetic model to predict rifampin exposures in bone. (C) Efficacy studies in mice compared vancomycin alone to vancomycin with either standard-dose or high-dose rifampin. Readouts included weekly in vivo bioluminescence, bacterial load and broth cultures at completion of follow up and CT to evaluate adverse bone remodeling. Bacterial isolates were evaluated for phenotypic resistance as well as subjected to whole genome sequencing. Human studies were approved by the Johns Hopkins University Institutional Review Board Committee. Patients were prospectively recruited at the Johns Hopkins Hospital and 11C-rifampin PET was performed under the U.S. FDA Radioactive Drug Research Committee program guidelines for investigational drugs. Animal studies were approved by the Johns Hopkins Animal Care and Use Committee. Approvals from the Johns Hopkins Biosafety, and Radiation Safety were also obtained for all studies. Results 11C-Rifampin PET median bone to plasma AUC ratio was 0.14 (IQR 0.09 – 0.19) in patients (Figure 2A-E), lower than previously reported using single time-point measures. Pharmacokinetic simulations and tissue measurements demonstrated that administration of high-dose rifampin leads to substantial increases in bone tissue concentrations (Figure 2F-G). Importantly, 4-weeks of high-dose rifampin administered in combination with vancomycin was non-inferior to the 6-weeks combination treatment with standard dose rifampin and vancomycin, recommended by the IDSA [risk difference: -6.7% (-20% – 6.9%) favoring high-dose rifampin] (Figure 3). Finally, high dose rifampin ameliorated antimicrobial resistance (0% vs 40%; P = 0.04), genetic alterations related to persistence (whole-genome bacterial sequencing) (Figure 4A-B) and mitigated adverse bone remodeling (high-resolution computed tomography) (Figure 4C-D). Figure 2. Rifampin bone exposures. (A) Three patients with S. aureus bone infections underwent dynamic 11C-rifampin PET for 60-90 minutes, followed by a CT scan. Frontal view of maximum intensity projection (PET) is shown. Note an implant in the left tibia (arrow). (B) 11C-Rifampin PET area under the concentration-time curve (AUC) shown as a heat map overlay in the selected transverse section. (C) Representative human time-activity curve (TAC). (D) 11C-rifampin exposure in human is shown as AUC ratio of bone to plasma, corrected for hematocrit and tissue density. Whenever possible infected bone was compared to uninfected contralateral bone. Plasma exposures were measured by drawing volumes of interest (VOI) in the left ventricle. (E) Dynamic 11C-rifampin PET in control patients (with pulmonary TB; from an unrelated study) (n = 12 patients). VOIs were drawn in uninfected bone as indicated. Mice were instrumented with a femoral Kirshner wire and infected with Methicillin-resistant S. aureus (SAP231) and followed for 2 weeks before antibiotic treatment was initiated with vancomycin and rifampin (BID dosing), corresponding to a human equipotent rifampin dose of 10, 35 and 45 mg/kg/day. Rifampin plasma (F) and bone (G) concentrations were measured by mass spectrometry in postmortem samples at 4 hours after last rifampin oral dose. (H) Mice underwent dynamic 11C-rifampin PET for 60 minutes following at least two weeks of antibiotic treatment, followed by a CT scan (n = 8 animals). Frontal view of maximum intensity projection (PET) is shown. Note the implant in the right knee (arrow). (I) Representative mouse TAC showing rapid decrease in plasma levels and accumulation in the liver. (J) 11C-Rifampin exposure in mouse shown as AUC ratio of bone to plasma (corrected for hematocrit) and tissue density using the mean Hounsfield units per VOI. VOIs were drawn for the infected femur (distal 25%) and the uninfected contralateral femur. Plasma exposures were measured by drawing VOI in the left ventricle. *p<0.05, †p<0.01 and ‡p < 0.001 as shown by the Kruskal-Wallis test (panels E, F and G) or by the Wilcoxon matched-pairs signed rank test (panel D), both adjusted for multiple comparisons to preserve the desired false discovery rate or by the 2-tailed Mann-Whitney test for comparison of infected to uninfected bone (panels G and J). Figure 3. Non-inferiority study in mice with S. aureus-implant infection. (A) Vancomycin and rifampin were initiated 2 weeks after infection (designated as day 0) and continued for 6 weeks (IDSA regimen, standard dose rifampin; n = 45 animals) or for 4 weeks (high-dose rifampin; n = 45 animals). Standard- and high-dose rifampin doses were (human equipotent) 10 and 35 mg/kg/day respectively. Monotherapy with vancomycin over 6 weeks was also performed (n = 10 animals). Stable cure was assessed at day 84 by assessing sterilization of the tissues and the implant. (B) Representative in vivo bioluminescent images from mice in each group. (C) Mean maximum flux (photons/s/cm2/sr) (and SEM). LOD = level of detection (3x103 photons/s/cm2/sr). (D) Six weeks after completion of antibiotic treatment, peri-implant joint and bone tissue were homogenized, implants were sonicated, and colony forming unit (CFUs) were enumerated ex vivo. Data are presented as the mean number of CFUs (and SEM) isolated from the peri-implant bone and joint tissue. (E) To evaluate whether the antibiotic therapy eradicated infection, tissue homogenates and implants were cultured for an additional 48 hours in broth followed by overnight plate culture and the presence or absence of bacterial growth was determined. Data are presented as the percentage of tissue samples with any bacterial growth. (F) Statistical analysis showing treatment difference in favor of high-dose rifampin and 90% confidence interval within the pre-set limit for non-inferiority (d=10%). *p<0.05, †p<0.01 and ‡p < 0.001 as shown by the Kruskal-Wallis test adjusted for multiple comparisons to preserve the desired false discovery rate. Figure 4. Bacterial characteristics and bone remodeling. All isolates from the non-inferiority study (Fig. 3; n = 21 isolates) were subjected to (A) phenotypic rifampin resistance testing (BD Phoenix) with results presented as the percentage of resistant isolates for each treatment group and (B) whole genome sequencing (Illumina; MiGS, Pittsburg, PA) and compared to the parent strain SAP231. Heat maps display isolates with variants in genes related to rifampin resistance (rpoB) or to bacterial persistence (lysM, sdhB and clfB). (C) Representative 3D reconstructed µCT images (opaque [top] and translucent [bottom] femora with implants in red). (D) Mean (and SEM) volume of the distal 25% of the infected femurs. *p<0.05, †p<0.01 and ‡p < 0.001 as shown by the Chi-square test (A) or by the Kruskal-Wallis test adjusted for multiple comparisons to preserve the desired false discovery rate (D). Conclusion Standard dose rifampin achieves sub-therapeutic levels in bone which can be substantially increased with higher doses. High dose rifampin ameliorates antimicrobial resistance and mitigate bone remodeling, facilitating shorter treatment in mice. Clinical studies are needed to examine the safety and efficacy of high dose rifampin for staphylococcal bone infections in humans. Disclosures Alvaro A. Ordonez, MD, Cubresa (Consultant)Fujirebio Diagnostics (Research Grant or Support) Robert Dannals, PhD, Precision Molecular Imaging (Consultant) Nathan Archer, PhD, Boehringer Ingleheim (Grant/Research Support)Integrated Biotherapeutics (Grant/Research Support)Pfizer (Grant/Research Support) Lloyd Miller, MD PhD, Armirall (Consultant)AstraZeneca (Consultant, Grant/Research Support)Boehringer Ingelheim (Grant/Research Support)Integrated Biotherapeutics (Board Member, Consultant)Janssen Research & Development, the pharmaceutical company of Johnson & Johnson (Consultant, Employee, Shareholder)Moderna Therapeutics (Grant/Research Support)Noveome Biotherapeutics (Shareholder)Pfizer (Grant/Research Support)Regeneron Pharmaceuticals (Grant/Research Support) Sanjay K. Jain, MD, Fujirebio Diagnostics, Inc., USA (Research Grant or Support)Novobiotic LLC, USA (Research Grant or Support)T3 Pharma, Switzerland (Research Grant or Support) Sanjay K. Jain, MD, Fujirebio Diagnostics, Inc., USA (Individual(s) Involved: Self): Research Grant or Support; Novobiotic LLC, USA (Individual(s) Involved: Self): Research Grant or Support; T3 Pharma, Switzerland (Individual(s) Involved: Self): Research Grant or Support